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Summary
The co-receptor CD8 plays an important part in the proper functioning of
cytotoxic T lymphocytes. In order to sense stimuli, the T cell surface recep-
tor (TCR) engages peptide-specifically with its ligand pMHC, while CD8
makes peptide-unspecific contact to the MHC subunit. In this work, the
entirety of interactions between TCR, CD8, and pMHC are elucidated by
confronting of a family of mathematical pMHC-TCR-CD8 interaction mod-
els with accurately measured dose response data. The interaction model
being in best agreement with the data, termed CBM, consists of a TCR-
CD8 complex having the striking property that its CD8 subunit exhibits
increased affinity to pMHC compared to CD8 alone.
A T cell triggering model, founded on multivalent binding, is con-
structed that enables affinity-based ligand discrimination. In combination
with CBM, the TCR triggering model is capable to correctly predict key
aspects of dose response T cell activation data, and introduces a novel
mechanism for the contribution of CD8 in ligand discrimination and T cell
activation. The high affinity CD8 binding site of the TCR-CD8 complex
prevents low affinity (self) ligands to establish pMHC-TCR contacts and
thereby reducing the intracellular signal intensity in response to self pep-
tides. High affinity (foreign) ligands, on the other hand, can counteract
by forming pMHC-TCR contacts with TCR-CD8 complexes. Because CD8
also binds the kinase Lck, this leads to enhanced intracellular signal in-
tensity in response to foreign antigen. Thus, CD8 amplifies affinity-based
ligand discrimination and the proposed mechanism leads to improved self
tolerance as well as sensitivity towards foreign antigen of T cells allocating
CD8 a significant contribution to T cell immunity.
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Zusammenfassung
Der Korezeptor CD8 tra¨gt zur reibungslosen Funktionsweise von zytotoxis-
chen T-Lymphozyten einen wichtigen Anteil bei. Zur Reizerkennung bindet
der T-Zell-Oberfla¨chenrezeptor TCR peptid-spezifisch an den pMHC Ligan-
den, wa¨hrend das CD8 peptid-unspezifisch mit dem MHC Teil interagiert.
Um die Gesamtheit der vorliegenden Wechselwirkungen zwischen TCR,
CD8 und pMHC zu untersuchen, werden in dieser Arbeit mehrere pMHC-
TCR-CD8 Interaktionsmodelle aufgestellt und mit genau bestimmten Do-
siswirkungs-Messwerten konfrontiert. Das Interaktionsmodell, welches die
gro¨ßte U¨bereinstimmung mit den vorliegenden Daten aufweist, wird CBM
genannt, und verfu¨gt u¨ber einem TCR-CD8-Komplex mit der unerwarteten
Eigenschaft einer, im Vergleich zu freiem CD8, erho¨hten Affinita¨t der CD8
Untereinheit fu¨r pMHC.
Auf multivalenter Bindung basierend, wird ein T-Zell Triggermod-
ell aufgestellt, dass es ermo¨glicht, Liganden bezu¨glich ihrer Affinita¨t zu
unterscheiden. Durch Kombination der Triggermodells mit CBM ko¨nnen
wesentliche Aspekte von Dosiswirkungsdaten der T-Zellaktivierung korrekt
wiedergegeben werden. Des Weiteren wird dadurch ein neuartiger Mech-
anismus des Beitrags von CD8 zur Ligandenunterscheidung sowie zur T-
Zellaktivierung eingefu¨hrt. Durch die CD8 Untereinheit des TCR-CD8
Komplexes, welche eine hohe Affinita¨t aufweist, wird die Ausbildung von
pMHC-TCR Bindungen bei Liganden mit niedriger Affinita¨t (Selbst-Pepti-
de) verhindert und dadurch die intrazellula¨re Signalsta¨rke verringert. An-
dererseits ko¨nnen Liganden mit hoher Affinita¨t (Fremd-Peptide) dem entge-
genwirken indem sie pMHC-TCR Bindungen mit dem TCR-CD8 Komplex
ausbilden. Da CD8 außerdem die Kinase Lck bindet, ruft fremdes Antigen
eine erho¨hte intrazellula¨re Signalsta¨rke hervor. Somit versta¨rkt CD8 die
affinita¨tsbezogene Ligandenunterscheidung und der vorgeschlagene Mecha-
nismus fu¨hrt zu einer Verbesserung sowohl der Selbsttoleranz als auch der
ix
Sensitivita¨t bezu¨glich Fremdantigenen von T-Zellen. Dadurch wird CD8
ein wesentlicher Beitrag zur T-Zellimmunita¨t zugesprochen.
x


1 Introduction
1.1 Ligand recognition by T cells
Cytotoxic T cells (CTLs) play a central role in the adaptive immune sys-
tem, as they constantly scan the surface of body cells for pathogen-derived
antigen. Virtually all body cells express major histocompatibility com-
plex of class I molecules (MHC) on their surface to which short peptide
fragments (pMHC) of usually 8–10 amino acids are bound. Because the
peptides are derived from the intracellular protein pool, such antigen pre-
senting cells (APCs) are mirroring their internal protein state onto their
cell surface allowing CTLs to target infected or otherwise damaged cells
[52]. The key player on the surface of CTLs participating in the process of
antigen recognition is the T cell receptor (TCR), which comprises of a lig-
and recognition unit and an intracellular signaling module [70]. The ligand
recognition unit, which makes contact to pMHC, is a dimer, which in its
most common form is composed of a highly variable α and β chain [52]. It
possesses a single binding site for pMHC, and typical dissociation constants
of TCR binding to agonist ligand were determined to range from 1 µM to
50 µM, with the half-life of the interaction on the order of seconds [18]. If a
foreign antigen is detected by the TCR, this information is transduced via
the signaling module. It comprises of three dimers: CD3γ, CD3δ, and
CD3ζζ [70]. All three units carry conserved regions known as immunore-
ceptor tyrosine-based activation motifs (ITAMs) [64]. Upon appropriate
contact between pMHC and TCR, ITAMs get phosphorylated by the Src
family kinase Lck [57]. Phosphorylated ITAMs are the target of Syk family
kinase ZAP70, which, if bound to an ITAM, gets in turn phosphorylated
by Lck [10, 57]. It is only in this state in which the TCR complex possesses
enzymatic activity and initiates the intracellular signaling cascade leading
to T cell activation [70].
1
1 Introduction 2
The functionality of the adaptive immune system critically depends
on the reliable discrimination of self peptides from foreign antigens. If the
presence of antigens, for which the TCR expressed on the surface of the in-
volved CTL possesses a respective specificity, is encountered on the surface
of a targeted APC, the information is transmitted to the interior of the T
cell via the TCR signaling module. In response, a vast signaling machin-
ery is switched on leading ultimately to the killing of the target APC as
well as to the secretion of cytokines into the extracellular environment [52].
Importantly, T cells exhibit a striking self tolerance, i.e. no such actions
are carried out if only self peptides are presented. However, even minute
amounts of foreign antigens, embedded in a large pool of self peptides, are
sufficient to trigger T cell activation [76, 38, 61] indicating that T cells
have a remarkable sensitivity towards their cognate antigen. Furthermore,
it has been shown that by altering a single amino acid of the peptide, the
pMHC ligand can loose its ability to trigger the TCR or can become an
antagonist [69]. Nevertheless, T cells are not restricted to a single antigen,
as the same TCR can respond to unrelated peptides bound to the same
MHC [24]. Thus, T cells are highly self tolerant, show poly-specificity, and
a remarkable sensitivity towards their antigens.
The mechanism by which T cells process the information provided
by the receptor-ligand interactions is still under debate. In the following,
some of these mechanisms are briefly discussed. The kinetic proofreading
[49] and discrimination [62] models propose that, upon pMHC-TCR con-
tact, a series of modification steps have to be completed in order to trigger
T cell activation. If pMHC dissociates from the TCR before, the molecules
will convert to their unmodified form [49, 62]. Hence, the off-rate of the
pMHC-TCR interaction plays the key role in these models. However, it
has been argued that these models achieve only few false positive events,
but pay for this by a considerable loss of sensitivity [11]. Improvements
were made by extending kinetic proofreading with additional mechanisms.
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Kinetic-segregation proposes that phosphatases exhibiting long extracellu-
lar tails, like CD45, are excluded from the sites of pMHC-TCR contact,
thereby allowing kinases like Lck to operate more efficiently [19]. The ob-
servation that a single antagonist pMHC can engage and trigger up to
200 TCRs led to the development of the serial triggering model [80]. In
combination with kinetic proofreading, it hypothesizes that pMHC-TCR
interactions must be sufficiently long to induce proximal signaling but also
sufficiently short to allow several TCRs to be stimulated, and thereby pre-
dicting an ’optimal dwell time’ [81, 15]. A further extension includes a
negative feedback mediated by the phosphatase SHP-1 [27]. Besides mech-
anism relying on the off-rate of pMHC-TCR interaction as most critical pa-
rameter of T cell antigen recognition, several models exist arguing in favor
of affinity. In the conformational change model, it is assumed that ligand
engagement with TCR induces a conformational change in the TCR/CD3
complex allowing for initiation of proximal signaling [31, 32]. A refinement
of the conformational change model, termed permissive geometry model,
has been proposed in that only multimeric pMHC binding induces a confor-
mational change [50]. Furthermore, the aggregation of TCRs into ’micro-
clusters’ following ligand engagement has been observed [87, 82] and used
to explain T cell activation [67]. This shows that a vast amount of, not
necessarily mutually exclusive, models have been considered to explain T
cell antigen recognition.
Under physiological conditions, CTLs interact with APCs, but, nev-
ertheless, it was demonstrated that CTLs can also be stimulated by soluble
pMHC [4]. At first sight, the conception that the affinity is the most critical
parameter poses a serious problem on how discrimination can be achieved.
To see why, consider a ligand L binding to receptor R with affinity K.
Then, the fraction of ligand-bound receptors is given by KL/(1 + KL).
Thus, it is not the affinity alone but the product of affinity and ligand con-
centration that determines receptor occupancy. Hence, low affinity can be
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compensated by high concentration, and ligand discrimination is compro-
mised. For models relying on the off-rate, like kinetic proofreading, this
aspect is of no concern, because even at saturated occupancy, the amount
of triggered TCRs is low if the dwell time does not match [49]. On the other
hand, it has been shown that soluble monomers are not sufficient to activate
T cells, but stimulation with dimers or larger oligomers is required [6, 74].
Indeed, for T helper cells, up-regulation of CD69 and CD25 – both being
surface marker for T cell activation – as well as down-regulation of CD3 can
be accurately described by a multivalent binding model [73]. Multivalent
ligand engagement offers the possibility of T cell antigen discrimination,
and detailed discussions of multivalent ligands binding to a single receptor
type have been published [59, 58]. In its simplest form, the ligand L is a
dimer possessing of two identical binding sites interacting with a receptor
R having a single binding site, as shown in Fig. 1A. One of the two ligand
subunits binds to a receptor with rate kon forming a monovalent complex
C1, which dissociates with rate koff. The unbound ligand subunit of a
complex C1 can further bind a receptor with rate qon forming a bivalent
complex C2. From this complex, one ligand subunit can dissociate with
rate qoff. The corresponding set of equations is given by
dC1
dt
= 2 konLR− koffC1 −
[
qonC1R− 2 qoffC2
]
, (1a)
dC2
dt
= qonC1R− 2 qoffC2 , (1b)
Rtot = R+ C1 + 2C2 , (1c)
with Rtot the total receptor density. Defining the dimensionless bivalent
association constant by q ≡ Rtot qon/qoff, the steady state of the fraction of
bivalently engaged receptors y2 ≡ C2/Rtot is given by
y2(L) = 1− (1 + 2KL)
2
4 q KL
·
[√
1 +
8 q KL
(1 + 2KL)2
− 1
]
. (2)
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Figure 1: Bivalent ligand engagement
(A) The reaction scheme of bivalent ligand engagement. One of the two identical ligand subunits
(black dots) binds to receptor (Y shape) with rate kon to form a monovalent complex. This complex
can either dissociate with rate koff, or the unbound ligand subunit binds another receptor with rate
qon forming a bivalent complex. From this, one of the two bound ligand subunits can dissociate with
rate qoff. Only those receptors bound in bivalent complexes are capable of initiating downstream
signaling (indicated by the arrow). (B) The maximum fraction of bivalently bound TCRs, y2,textmax,
in dependence on the bivalent association constant q. (C) The fraction of ligand-bound (dashed curves)
and bivalently bound (full curves) receptors in dependence on ligand concentration for high (red), mid
(purple), and low (blue) affinity ligands. The bivalent association constant has been set proportional
to the binding affinity. The fraction of ligand-bound receptors reaches saturation independent of ligand
quality. Bivalent binding discriminates ligands according to affinity since low affinity ligands fail to
establish a effectual amount of bivalently bound receptors.
Relation (2) describes a bell-shaped curve with a peak at the concentration
value L∗ = 1/(2K). The bell-shape is a consequence of ligands in solu-
tion competing with monovalently bound ligands for unoccupied receptors.
At low concentrations, many TCRs are unbound and monovalently bound
ligands can engage with a second receptor. However, at high concentra-
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tions, most TCRs are bound by a ligand and multivalent engagement is no
longer possible. This results in a bell-shaped curve of multivalent binding
[59]. The peak value in dependence on the bivalent association constant,
y2,max(q), is given by
y2,max(q) = 1− 2
q
[√
1 + q − 1
]
, (3)
and is a strictly increasing function of q, i.e. y′2,max(q) > 0. Hence, the
larger q the larger the peak value, see Fig. 1B. Assuming that only bi-
valently bound TCRs induce intracellular signaling (arrow in Fig. 1A),
ligands with sufficiently large bivalent association constant are capable of
activating T cells. This is shown in Fig. 1C for q ∼ K [75]. The larger
the affinity the more bivalently bound TCRs are established, and low affin-
ity ligands fail to elicit T cell activation. Therefore, ligand discrimination
based on affinity can also be achieved by soluble pMHC.
1.2 Impact of co-receptor CD8
Ligand recognition and signal initiation are accompanied by the co-receptor
CD8. CD8 is a transmembrane cell surface protein existing in two forms; as
αα homodimer and αβ heterodimer [52], with the αβ isoform being found
on most CTLs [56]. CD8 is thought to contribute to T cell activation
by enhancing sensitivity to pMHC [38, 36] and by stabilizing pMHC-TCR
interactions [47, 86]. However, CD8 is not always indispensable as some
ligands can trigger T cell activation in the absence of CD8 [16, 13, 46].
These effects are attributed to the participation of CD8 in intracellular
signal initiation and binding of presented pMHC [45].
The main contribution of CD8 in enhancing sensitivity in T cell
antigen discrimination comes from the association of CD8 with the kinase
Lck [83, 79], and established the notion of CD8 acting as a T cell co-
receptor [40]. This view is also supported by the finding that CD8 binds
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MHC at a highly conserved region [66, 65], which is distal to the binding
site of pMHC-TCR interactions [30]. This interaction was determined to
be of relatively fast kinetics (koff ≈ 20 s−1) and low affinity (KD between
100 µM and 220 µM for human, and 15 µM and 135 µM for murine CD8)
[14]. Importantly, it was suggested that a TCR and a CD8 co-receptor
can bind the same pMHC [30]. Several studies also indicated that there
is a physical interaction between the TCR and CD8 on the cell surface
[77, 29, 5]. In particular, the α-chain connecting peptide motif of the TCR
has been identified as agent recruiting CD8 to the TCR/CD3 complex
[55, 48]. Hence, CD8 can deliver Lck to the site of pMHC-TCR contact
and therby enhancing sensitivity as well as stabilizing the pMHC-TCR
interaction.
1.3 Outline of the thesis
In Sec. 1.2, the contributions of co-receptor CD8 to T cell antigen recogni-
tion and activation were outlined. However, the models of antigen recog-
nition described in Sec. 1.1 do not account for CD8 explicitly. It is there-
fore the aim of this work to identify the mechanistic interactions between
pMHC, TCR, and CD8 and to relate them to T cell antigen recognition.
In Chap. 2, the statistical framework used in this work for model
fitting, parameter estimation, and model selection is outlined. Based on
the remarks made in this chapter, a family of pMHC-TCR-CD8 interaction
models is developed in Chap. 3. These models are suited to account for
cell surface receptor interactions with multivalent soluble ligands, which is
exploited in Chap. 4 to select the binding model that fits accurately mea-
sured dose response binding data best. Furthermore, the model parameters
are estimated and assigned with confidence intervals. The properties of the
chosen model concerning receptor occupancy, multivalent binding and TCR
triggering are outlined in Sec. 5. Additionally, in Chap. 6, the model is
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placed in the context of antigen presenting cells to investigate whether the
found attributes are preserved in more lifelike situations. Finally, the find-
ings are discussed and placed in context in Chap. 7.
2 Statistical methods
A central task of this work is to find a binding model describing the inter-
actions between pMHC, TCR, and CD8 and to estimate the corresponding
model parameters. This is achieved by a statistically rigorous confrontation
of experimental data with the corresponding observable calculated for each
model of a set of candidate models. The determination of this observable
is outlined in Chap. 3. In the following, it is described how the models are
fitted to the data, parameter confidence intervals are estimated, and the
best-fitting model is selected.
2.1 Maximum likelihood estimation
Consider a set of n independent data points, (xi)i=1,...,n, generated by ran-
dom variables with probability density functions fi(x | θ). For different i,
the density functions can assume divers functional froms, but all density
functions share a common set of parameters θ. Once all data xi is gathered
and therefore fixed, the likelihood function L, defined as the joint density
function of all observations, is regarded as a function of the parameters θ,
L(θ) :=
n∏
i=1
fi(xi |θ) . (4)
The aim is to find an estimate for the true value θ0 of the parameter vector θ
based on the data. The principle of maximum likelihood estimation (MLE)
delivers such an estimate by calculating the value θMLE that maximizes the
likelihood function (4) [1, 26]. It is usually more convenient to consider the
log-likelihood function l, which is defined as the natural logarithm of the
likelihood function,
l(θ) := lnL(θ) =
n∑
i=1
ln fi(xi |θ) . (5)
9
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Since ln is a monotonically increasing function, maximizing (5) is equivalent
to maximizing (4). Therefore, MLE is performed by
θMLE ≡ arg max
θ
l(θ) , (6a)
lmax ≡ l(θMLE) . (6b)
The point estimate θMLE itself does not contain any information about
uncertainties of that estimate. Estimation of parameter uncertainties is
achieved by using the method of profile likelihood. This procedure, as well
as model selection, involves the value lmax. But before these two aspects
are further outlined, an important special case of MLE is discussed.
2.2 Least squares estimation
Assume all probability density functions fi are given by normal distribu-
tions with unknown mean yi(θ) but known standard deviation σi,
fi(x | θ) := 1√
2pi σ2i
exp
[
−1
2
(
yi(θ)− x
σi
)2]
. (7)
This means that, for each i, only the functions yi depend on the parameters
θ. In particular, yi(θ) is the observable of condition i calculated from the
model under consideration. The corresponding log-likelihood function (5)
becomes
l(θ) = −1
2
n∑
i=1
[(
yi(θ)− xi
σi
)2
+ ln
(
2pi σ2i
)]
. (8)
Since only parameter-dependent terms impact function maximization, each
term of the form ln
(
2pi σ2i
)
can be dropped, and maximum likelihood es-
timation becomes equivalent to least squares estimation, with the least
squares function given by
χ2(θ) :=
n∑
i=1
(
yi(θ)− xi
σi
)2
. (9)
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Hence, procedure (6) now reads
θMLE ≡ arg min
θ
χ2(θ) , (10a)
χ2min ≡ χ2(θMLE) = −2 lmax . (10b)
In the framework of least squares estimation, the value χ2min can be ex-
ploited to access the quality of the fit via the goodness-of-fit (gof) param-
eter,
gof ≡ χ
2
min
n− |θ| , (11)
with n the total number of data points and |θ| the number of model pa-
rameters. Hence n− |θ| denotes the degrees of freedom of the fit. A value
of gof close to 1 indicates a good agreement between model and data.
2.3 Profile likelihood
To assess the uncertainties of the model parameters in terms of confidence
intervals, the method of profile likelihoods is used [53, 84]. This method
explores the local neighborhood of the MLE value θMLE, and considers
those points of the parameter space acceptable whose log-likelihood value
deviates not too much from lmax. The profile likelihood function of the j-th
model parameter is defined by [43, 63]
PLj(p) := min
θ∈{θ|θj=p}
− 2 l(θ) . (12)
Thus, the log-likelihood function is optimized with the j-th parameter θj
being fixed to the value p. For a sufficiently large number of data points,
the confidence interval of the j-th parameter at confidence level α is given
by [43, 63]
CIα(θj) := {p | PLj(p) ≤ −2 lmax + ∆α} , (13)
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with ∆α the α-quantile of the chi-squared distribution with one degree of
freedom. For a 95 % confidence interval it holds ∆a = 3.84. This procedure
is repeated for all model parameters delivering the independent confidence
intervals of the model parameters at confidence level α.
2.4 Prediction profile likelihood
The profile likelihood method allows for estimation of confidence intervals
for model parameters. If the quantity of interest, to which a confidence
interval has to be assigned, is of the more general form W (θ), a similar
strategy can be applied, which goes under the name prediction profile like-
lihood [43, 44]. The prediction profile likelihood function of prediction
W (θ) is defined by
PPL(z) := min
θ∈{θ|W (θ)=z}
− 2 l(θ) , (14)
Thus, optimization is only performed on the subset of parameters obey-
ing W (θ) = z. In analogy to (13), the prediction confidence interval at
confidence level α is given by [43, 44]
PCIα(W ) := {z | PPL(z) ≤ −2 lmax + ∆α} . (15)
2.5 Model selection
If several different models are considered for describing the same data set,
a strategy is required that allows for choosing the model in best agree-
ment with the data. Such a strategy of model selection is provided by the
corrected Akaike Information Criterion (AICc) [8]. It is defined by
AICc ≡ −2 lmax + 2 |θ|+ |θ| (|θ|+ 1)
n− |θ| − 1 , (16)
and balances between the quality of the fit, represented by −2 lmax, and the
size of the model in terms of the number of model parameters |θ|. However,
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a model’s AICc value itself has no meaning. Instead, the AICc value of the
model having the smallest value AICc,min serves as reference. The difference
of a model’s AICc value to that reference, i.e.
∆AICc = AICc −AICc,min , (17)
is the central quantity to perform model selection. Following the recommen-
dation in Burnham and Anderson [8], a model is rejected if ∆AICc > 10
holds. Thus, model selection via ∆AICc is a relative procedure in that
always a best model is selected. No statement is made about the actual
quality the selected models perform on the data.

3 A family of pMHC-TCR-CD8 interaction mod-
els
In Sec. 1.2, several findings concerning the contribution of CD8 to ligand
binding were discussed. Based on that, a family of pMHC-TCR-CD8 bind-
ing models is developed in this chapter. To assure an unbiased view on
the matter, it is started with a simple binding scheme whose complexity
is increased stepwise by incorporation of further CD8-dependent reactions.
All models are considered at thermodynamic equilibrium, as data acquisi-
tion – described in Chap. 4 – was performed under such conditions. At
first, the models are introduced for monomeric pMHC clarifying the prin-
cipal reactions to which the receptors and ligands are subject to. Next, the
models are generalized to account for multimeric pMHC and rescaling of
model parameters is performed. To obtain a unified treatment, the models
are placed in the framework of binding polynomials [21], and conservations
of receptor numbers is taken into account. Finally, the amount of bound
ligands is determined, which serves as observable for model selection and
parameter estimation in Chap. 4.
3.1 Binding models for monomeric pMHC
At first, the binding model family is set up for monomeric pMHC serving
as ligands. The reaction schemes of the binding models are depicted in Fig.
2. The first model comprises only a single reaction; TCR binds reversibly
to pMHC with affinity K1 (Model A, Fig. 2A). This model is suited for T
cells lacking the expression of CD8.
Incorporation of CD8 into ligand binding is initially done implicitly.
The co-receptor does not appear as a binding partner, but instead affects
the affinity of pMHC-TCR binding via a scaling factor ε (Model B, Fig.
2B). Hence, ligand binding is described by apparent binding affinities.
15
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Figure 2: Monomeric binding models
The models of pMHC and TCR interaction (A) as well as pMHC, TCR, and CD8 interactions (B–G)
are shown. The details are outlined in the main text. (A) pMHC binds to TCR from solution. (B)
pMHC binding to TCR is enhanced by CD8. (C) pMHC can either bind to a TCR or to a CD8
co-receptor. (D) Additionally, TCR and CD8 can bind to the same pMHC. (E) If a TCR and a CD8
are in simultaneous contact with a pMHC, the two receptors can bind to each other. (F) Furthermore,
TCR-CD8 complex formation is possible in the absence of pMHC. The TCR-CD8 complex possesses
a single binding site. (G) A TCR-CD8 complex with two binding sites, one stemming from the TCR
and the other one from CD8, can form. Next to binding to TCR or to CD8, pMHC can bind to
the TCR or to the CD8 binding site of a TCR-CD8 complex. TCR and CD8 can further bind pMHC
simultaneously, and all three molecules can make complete contact. The green, dashed frames in (E–G)
indicate that these states are indistinguishable under the experimental conditions, and merged into a
single aggregated state.
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The first model accounting for CD8 explicitly comprises of two basic
reactions. A pMHC can either bind reversibly to a TCR with affinity K1
or to a CD8 co-receptor with affinity K ′1 (Model C, Fig. 2C). Importantly,
K ′1 is not affected by altering the peptide of pMHC since CD8 makes only
contact to MHC.
Next, the possibility of both receptors binding to the same pMHC is
accounted for (Model D, Fig. 2D). In addition to pMHC-TCR and pMHC-
CD8 binding, a TCR-bound pMHC can engage with a CD8 with asso-
ciation constant K ′2 to form a trimolecular complex. Alternatively, this
complex can also be established if a TCR binds to CD8-bound pMHC with
association constant K2. Because K
′
2 describes a reaction in which CD8
binds pMHC, it is, like K ′1, independent of the peptide. Note that detailed
balance imposes dependences between the parameters; these are discussed
below.
The previous model is extended to include a direct TCR-CD8 inter-
action (Model E, Fig. 2E). If pMHC is bound simultaneously to TCR and
CD8, the two receptors can bind to each other with association constant
Q2. Importantly, the two trimolecular binding states cannot be distin-
guished by the binding experiments outlined in Sec. 4.1. The reason is
that both these states are build up by the same receptors and ligands, and,
furthermore, pMHC makes contact to the TCR. These are the principal
aspects by which the binding experiments can separate different binding
states, because only dose and peptide quality were altered (see Sec. 4.1).
All further binding characteristics, like a bond between TCR and CD8, are
therefore not resolved. Hence, these states are merged into a single aggre-
gate state, which is indicated by the green, dashed frame. Due to this state
aggregation, Model E becomes indistinguishable from Model D.
The next model extension comprises of a ligand-independent inter-
action between TCR and CD8 (Model F, Fig. 2F). The two receptors can
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form a complex with association constant Q1. Despite both receptors alone
can bind pMHC, the TCR-CD8 complex possesses only a single binding site
to which pMHC can bind with affinity K ′′1 . As before, this model contains
indistinguishable binding states indicated by the green, dashed frame. The
corresponding state aggregation follows the same arguments as above.
The final model also allows for a pMHC-independent formation of a
TCR-CD8 complex with association constant Q1 (Model G, 2G). Unlike the
two models before, this complex possesses two binding sites; one originating
from the TCR and the other from CD8 making the last one peptide un-
specific. Thus, additionally to the reactions described for Model D, pMHC
can either bind to the TCR binding site of the TCR-CD8 complex with
affinity K ′′1 or to its CD8 binding site with affinity K ′′′1 . Importantly, these
binding affinities must not be equal to the corresponding binding affini-
ties of pMHC to TCR, K1, respectively CD8, K
′
1. The binding state with
pMHC bound to the TCR binding site of a TCR-CD8 complex can also be
formed if CD8 binds to pMHC-bound TCR with association constant Q3.
Similarly, a TCR binding to pMHC-bound CD8 with association constant
Q4 yields the state with pMHC bound to the CD8 binding site of a TCR-
CD8 complex. Furthermore, a binding state in which pMHC, TCR, and
CD8 are in complete contact with each other can form in three different
ways. Either, pMHC makes contact to CD8 with association constant K ′′′2
if pMHC is already bound to the TCR binding site of a TCR-CD8 complex,
or pMHC makes contact to the TCR with association constant K ′′2 if pMHC
is already bound to the CD8 binding site of a TCR-CD8 complex, or TCR
and CD8 bind to each other with association constant Q2 if both receptors
are simultaneously bound to pMHC. Like K ′1, K ′′′1 , and K ′2, the parameter
K ′′′2 is independent of peptide quality. The model is further considered un-
der the condition Q3 ≥ Q1. The rationale behind this assumption is that,
following the arguments given in Sec. 1.2, pMHC binding to TCR should
not attenuate CD8 approaching the TCR. As Models E and F, Model G
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comprises of a set of states that cannot be distinguished by the binding
experiments. As before, these states are marked by a surrounding green,
dashed frame and merged into a single aggregate state.
At equilibrium, the number of independent parameters needed for
a complete description of the system equals the number of binding states.
The remaining parameters are determined by principle of detailed balance.
In case of the Model G (Fig. 2G), there are seven binding states (with
state aggregation not yet considered) and twelve model parameters. Hence,
detailed balance delivers five conditions,
K1K
′
2 = K
′
1K2 , (18a)
K1Q3 = K
′′
1 Q1 , (18b)
K ′1Q4 = K
′′′
1 Q1 , (18c)
K ′2Q2 = K
′′′
2 Q3 , (18d)
K2Q2 = K
′′
2 Q4 . (18e)
The set of independent parameters describing Model G is chosen to be
{K1,K ′1,K ′2, Q1, Q2, Q3, Q4} in which onlyK1 is peptide specific. The three
states in Fig. 2G that are surrounded by the green, dashed frame cannot be
distinguished by the experiments outlined in Sec. 4.1, and are thus merged
into a single state, which henceforth is termed aggregated state. Therefore,
the number of independent parameters reduces by three as well. From the
set of independent parameters, it follows that the corresponding effective
association constant Ξ (see Fig. 2) describing the aggregated state is given
by
Ξ ≡ Q3 +K ′2 (1 +Q2) , (19)
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Table 1: Parameter occurrence in monomeric binding models
The independent parameters used to describe the different binding models are shown. The two most
left columns comprise the parameter and a brief description thereof. The remaining columns indicate
the occurrence of the parameter by a cross. The model names refer to the subfigures of Fig. 2.
Model
A B C D E F GParameter Comment
Binding affinity of pMHC to TCR
CD8 related enhancement of pMHC-TCR affinity
Binding affinity of pMHC to CD8
TCR-CD8 complex formation
CD8 binding to pMHC-TCR (aggregated state)
TCR binding to CD8 of pMHC-CD8
K
1
K’
1
Q
1
Q
4
K’
2 
/ Ξ
ε
and the set of independent parameters describing monomeric Model G is
given by
ΘG,mono ≡ {K1,K ′1, Q1,Ξ, Q4} . (20)
Similar arguments are applied to the other binding models. The indepen-
dent parameters of Model F are obtained by removing Q4 from (20) and by
setting Q3 to zero in (19). Models D and E require additional elimination
of Q1 from (20) and, in case of Model D, setting of Q2 to zero in (19).
Further, the parametrization of Model C is attained by additional removal
of Ξ from (20). Parametrization of Model B is simply given by K1 and ε.
This is summarized in Tab. 1. The independent parameters occurring in
the different models are marked by a cross.
3.2 Incorporation of ligand multivalencies
The next step is to extend the monomeric interaction models to include
binding of multimeric ligands. The basic idea of incorporation of ligand
multivalencies was already outlined in Sec. 1.1. There, the association
constant of multivalent ligand binding was set proportional to the binding
affinity. This concept is pushed further in the following. The ligand under
consideration is an oligomer having ν identical binding sites or subunits.
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The effective ligand valency f is defined to be the maximal number of
subunits that can make contact to cell surface receptors simultaneously. At
first, incorporation of ligand multivalencies is outlined for a single receptor
type as it is the case for Models A and B (Fig. 2A and B). Then, the method
is generalized to account for a second receptor type as in Models C–G (Fig.
2C–G). Note that, in the following, no attention is paid to the statistical
weights of the binding states. These considerations are postponed to Sec.
3.4.
The general concept of modeling multivalent binding relies on the
assumption of a common multivalent engagement parameter KMV [75].
This involves two implications. Consider a ligand X, which binds from
solution to a given receptor type with affinity K1,X . If already k of the
ligand’s subunits made contact to k receptors, the first implication states
that the association constant of binding to a further receptor is given by
KMVK1,X for each k = 1, . . . , f − 1. If, however, f subunits are bound,
no further subunit can make contact to another receptor. This means that
after a ligand X binds from solution with affinity K1,X , each multivalent
binding reaction to a further receptor is determined by a single association
constant KMVK1,X until the maximal number of f subunits made contact.
The second implication concerns the comparison to another ligand type Y
having affinity K1,Y . It states that the association constant for ligand Y is
given by KMVK1,Y , and beyond that, the first implication holds. Hence,
multivalent binding is described for all ligands by the same two parame-
ters: the multivalent engagement parameter KMV and the effective valency
f . This is exemplified in Fig. 3A for a tetramer (ν = 4) with effective
valency f = 3. After binding from solution with affinity K1, the engage-
ment reactions from monomer to dimer as well as from dimer to trimer
are both specified by the same association constant KMVK1, which in turn
is determined by the multivalent engagement parameter. Further binding
from trimer to tetramer is prohibited due to the restriction of the effective
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ligand valency. In order to describe the same reactions for another ligand,
only the affinity needs to be adapted.
Fig. 3B shows all possible bivalent binding states grouped according
to the different binding models. The only bivalent binding state of Models
A and B, two pMHC subunits bound to TCR, is shown in the first column.
Model C comprises of two further bivalent states with one pMHC subunit
bound to CD8 (second column); the other subunit is either bound to TCR
(first row) or to CD8 (second row). Three additional bivalent states appear
in Models D, E, and F with one pMHC subunit bound via aggregated state
(third column); the other subunit is either bound to TCR (first row), to
CD8 (second row), or via aggregated state (third row). Lastly, Model G
contains four more bivalent states with one pMHC subunit bound to the
CD8 binding site of a TCR-CD8 complex (fourth column); the other one is
either bound to TCR (first row), to CD8 (second row), via aggregated state
(third row), or also to the CD8 binding site of a TCR-CD8 complex (fourth
row). It is assumed that the same approach used for a single receptor type
yields a reasonable outcome if a second receptor type is taken into account.
This means that only the receptor, to which a ligand’s subunit binds mul-
tivalently to, determines the association constant, and not how the ligand
was previously bound. This is indicated by the association constants shown
below each column and to the right of each row. The allocation is as fol-
lowing. If, for one of the depicted bivalent binding states, the ligand was
initially bound via the left subunit, binding to the receptor type to the right
is determined by the association constant at the right side of the row in
which the binding state is placed. Note that, in the first row, the receptor
on the right is always a TCR, in the second row always CD8, in the third
row always the aggregated state, and in the fourth row TCR-CD8 com-
plex with pMHC bound to its CD8 binding site. If the ligand was initially
bound via the right subunit, the association constant below the column in
which the binding state is placed determines multivalent binding with the
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Figure 3: Multivalent binding states
(A) Tetramer with effective valency f = 3 binding to TCRs. The tetramer binds from solution with
affinity K1 and subsequent formation of dimers and trimers are determined by a single association
constant KMV K1. Larger states than trimers cannot. (B) Bivalent binding states established by
tetramers grouped according to the different binding models. First column: Models A and B comprise
only of two cross-linked TCRs. Second column: Model C consists on top of states in which CD8 is
cross-linked to TCR, or to CD8. Third column: Models D, E, and F also include states in which an
aggregated state is cross-linked to TCR, or to CD8, or to an aggregate state. Fourth column: Model G
contains further states in which pMHC bound to CD8 binding site of TCR-CD8 complex is cross-linked
to TCR, or to CD8, or to an aggregated state, or to pMHC bound to CD8 binding site of TCR-CD8
complex. If the bivalent binding state is formed by binding to the receptor type appearing right in the
binding state, the association constant on the right of the row in which the binding state is located
is applied. If the bivalent binding state is formed by binding to the receptor type appearing left in
the binding state, the association constant below the column in which the binding state is located is
applied. In case of Model B, the association constant has further be corrected by the scaling factor ε.
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receptor type to the left. The arrangement of the left receptors per column
is similar to those for rows. For example, consider the binding state in
the first row and second column. It shows a tetramer with the left subunit
bound to a CD8 and the right to a TCR. If the tetramer was initially bound
to CD8, binding of the right subunit to TCR is determined by the associ-
ation constant KMVK1 (shown to the right of the first row), because K1
denotes the binding affinity of pMHC to TCR. Accordingly, if the tetramer
was initially bound to TCR, further binding to CD8 is determined by the
association constant KMVK
′
1 (shown below the second column). Of course,
the occupancy of a given binding state does not depend on the order by
which it was formed. Making contact to TCR in the second binding step
requires binding to CD8 in the first step with affinity K ′1. Vice versa, bind-
ing to CD8 in the second step necessitates contact of the ligand to TCR
with affinity K1. Hence, the occupancy of the binding state with one ligand
subunit being in contact with CD8 while another one is in contact with a
TCR is determined by KMVK
′
1K1 irrespective of the order of formation.
These arguments can be applied to all multivalent binding states including
those with larger valency than shown in Fig. 3B, i.e. trivalent or tetrava-
lent binding states. As above, the maximal number of pMHC subunits that
can make simultaneous contact to cell surface receptors is restricted by the
effective ligand valency f . The outlined methods allows for a treatment of
multivalent binding reactions for a ligand with given valency ν by only two
parameters, the multivalent engagement parameter KMV and the effective
ligand valency f .
The assumption that all multivalent binding reactions can be de-
scribed by only two parameters is of course very strong, and its validity
needs to be shown. The findings described in Sec. 5.3 indicate, however,
that the concept of a common multivalent engagement parameter seems to
be a reasonable choice. The great advantage of this approach is that a vast
number multivalent binding states can be described by a small number of
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parameters; this is very desirable in order to avoid overfitting [8].
3.3 Dimensionalities and rescaling of model parameters
The complete set of model parameters comprises the parameters of the
monovalent binding models and the two parameters used to describe mul-
tivalent binding,
Θ ≡ {K1, K ′1, ε, Q1, Ξ, Q4, KMV, f} . (21)
The binding affinities K1 and K
′
1 have the unit of an inverse concentration.
For any calculations to be performed, the concentration unit is chosen to
be µM. Thus the unit of the binding affinities is µM−1. The effective
ligand valency f and the enhancement factor ε are already dimensionless.
The association constants Q1, Ξ and Q4 have the unit of an inverse two-
dimensional density1, and the unit of the multivalent binding parameter
KMV is given by concentration over two-dimensional density. These four
parameters are rescaled with a two-dimensional reference density RT , which
is determined in Sec. 4.1,
q1 ≡ RT Q1 , (22a)
ξ ≡ RT Ξ , (22b)
q4 ≡ RT Q4 , (22c)
κMV ≡ RT KMV . (22d)
Hence, q1, ξ, and q4 are dimensionless, and κMV has the unit of a concen-
tration, i.e. µM. The full set of model parameters, from which each binding
model recruits its parameters (see Tab. 1), is thus given by
θ ≡ {K1, K ′1, ε, q1, ξ, q4, κMV, f} . (23)
1Two-dimensional densities have a unit of number over unit area.
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3.4 Formulation via binding polynomials
The binding models are equipped with a proper parameterization and the
ability to account for ligand multivalencies. Lacking is a useful framework
in which the models are set up for model selection and parameter estima-
tion. Such a framework is provided by the method of binding polynomials.
Binding polynomials allow for a unified treatment of equilibrium binding
as they represent the corresponding thermodynamic partition function [21].
Having a suitable representation of the model states at hand, the sum over
all states is formed yielding the binding polynomial of the model. Based
on the binding polynomial, receptor number conservation is taken into ac-
count to determine the densities of unbound receptors, which allows for
calculating the amount of bound ligands. This quantity is the observable
mentioned in Sec. 2.2, and is thus required in Chap. 4 to perform model
selection and parameter estimation.
For a given ligand type with effective valency, all binding models
developed above can be viewed as special cases of Model G. Therefore,
only the binding polynomial of Model G is derived in the following. The
corresponding binding polynomials of the other models are obtained by
setting those parameters to zero that are not marked by a cross in Tab.
1. In case of Model B, the additional replacement K1 → εK1 has to be
applied as well. Model G comprises of three states with no bound ligand:
TCR (T ), CD8 (C) and the TCR-CD8 complex forming with association
constant q1 (q1 T C). Note that due to the rescaling (22) by the reference
density RT , the receptor densities of TCR, T , and CD8, C, became also
dimensionless. The functional form of the density of each ligand-bound
state can be written to only depend on the density of unbound TCR T ,
the density of unbound CD8 C, the ligand concentration L, and a set of
parameters describing the way these constituents interact. The parameters
are recruited from the set (23). Each ligand-bound state is characterized
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by a set of four numbers, u = {u1, u2, u3, u4}, describing how many pMHC
subunits are bound in which way to the cell surface receptors. If a ligand
is bound according to binding state u, it has u1 pMHC subunits bound
only to TCR, u2 pMHC subunits only to CD8, u3 pMHC subunits via
aggregated state, and u4 pMHC subunits to the CD8 binding site of a
TCR-CD8 complex. This is illustrated in Fig. 4 for the case of a tetramer
(ν = 4) with effective ligand valency f = 3. The 4 monovalent ligand-
bound states were introduced in Sec. 3.1 aside from the fact that the
ligand is now a tetramer. The 10 bivalent ligand-bound states were the
subject of Sec. 3.2 where ligand multivalencies were incorporated into the
binding models. Allowing for trivalent ligand-bound states leads to further
20 states whose occupancies are similarly calculated as those of bivalent
ligand-bound states. In the further course, it is convenient to introduce to
following scaffold expressions for the four different ways a pMHC subunit
can be bound to the cell surface receptors,
S1(T,C | θ) := K1 T , (24a)
S2(T,C | θ) := K ′1C , (24b)
S3(T,C | θ) := ξ K1 T C , (24c)
S4(T,C | θ) := q4K ′1 T C . (24d)
These expressions contain the receptor densities and the principal param-
eter dependencies of the four monovalent binding states of Model G (Fig.
2G), and have the unit of an inverse concentration. To obtain the oc-
cupancy of a monovalent ligand-bound state, multiplication of the ligand
concentration L with the respective scaffold expression (24) is required2.
2An additional term accounting for the statistical weight has to be considered as well.
This is postponed to a later part of this section.
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trivalent binding states
TCR
CD8
pMHC
bivalent binding states
{3,0,0,0}
{1,0,2,0}
{2,1,0,0} {2,0,1,0} {2,0,0,1} {1,2,0,0} {1,1,1,0} {1,1,0,1}
{1,0,1,1} {1,0,0,2} {0,3,0,0} {0,2,1,0} {0,2,0,1} {0,1,2,0}
{0,1,1,1} {0,1,0,2} {0,0,3,0} {0,0,2,1} {0,0,1,2} {0,0,0,3}
{0,0,2,0} {0,0,1,1} {0,0,0,2}
{2,0,0,0} {1,1,0,0} {1,0,1,0} {1,0,0,1} {0,2,0,0} {0,1,1,0} {0,1,0,1}
{1,0,0,0} {0,1,0,0} {0,0,1,0} {0,0,0,1}
monovalent binding states
Figure 4: Ligand-bound states of Model G for tetramer with effective valency of 3
Each ligand bound state is characterized by a set {u1, u2, u3, u4} indicating the four different ways a
pMHC subunit can be bound to T cell surface receptors. Element uj represents the number of pMHC
subunits bound according to the j-th interaction type (j = 1, . . . , 4). The valency of a state is given by
m =
∑4
j=1 uj . The four monovalent binding states (m = 1) show the basic interactions between pMHC,
TCR, and CD8. Each pMHC subunit of a ligand can realize the same interactions as in the monovalent
case leading to 10 bivalent and 20 trivalent binding states. The corresponding parameterizations are
outlined in the main text. The arrows depict below some TCRs indicate the signaling capacity of these
TCRs. Thin arrows represent weak signaling TCRs lacking adjacent CD8, while thick arrows represent
strong signaling TCRs with increased signaling capacity due to the recruitment of kinase Lck by CD8.
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Subsequent multivalent binding is described by multiplying the multiva-
lent binding parameter κMV with the scaffold expression corresponding to
the new contact the pMHC subunit makes3. The total number of bound
pMHC subunits is m =
∑4
j=1 uj , which is constrained by the effective lig-
and valency, 1 ≤ m ≤ f . The first pMHC subunit binds from solution at
concentration L, and the remaining m − 1 pMHC subunits engage multi-
valently. Thus, the (dimensionless) density of state u, denoted by Xu, is
given by
Xu(T,C, L | θ) := gu · L · κm−1MV
4∏
j=1
Sj(T,C | θ)uj , (25)
with gu denoting the statistical weight of state u. It comprises of two terms.
The first term counts the number of ways to choose m pMHC subunits for
binding with cell surface receptors out of the ν total pMHC subunits, and
is therefore given by a binomial coefficient. The second term tallies the
number of ways to distribute the four possible bond types among the m
pMHC subunits, which is determined by a multinomial coefficient. Thus it
holds
gu ≡
(
ν
m
)
·
(
m
u1, u2, u3, u4
)
. (26)
The binding polynomial F is obtained by summing over all possible model
states,
F (T,C, L | θ) := T + C + q1 T C +
∑
u
Xu(T,C, L | θ) . (27)
The index set u runs over all non-negative integer values obeying m =∑4
j=1 uj with 1 ≤ m ≤ f . Thus one finds
F (T,C, L | θ) = T + C + q1 T C +
L
f∑
m=1
(
ν
m
)
κm−1MV
∑
u1,u2,u3,u4
u1+u2+u3+u4=m
(
m
u1, u2, u3, u4
) 4∏
j=1
Sj(T,C |θ)uj . (28)
3see footnote 2.
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The binding polynomial can be simplified to
F (T,C, L | θ) = T + C + q1 T C +
L
f∑
m=1
(
ν
m
)
κm−1MV
 4∑
j=1
Sj(T,C | θ)
m , (29)
by exploiting the multinomial theorem.
The experiments described in Sec. 4.1 were performed under condi-
tions that leave the total number of cell surface receptors unchanged during
the course of the experiment as well as for different experimental conditions.
These conservations of total TCR and total CD8 receptor densities are ac-
counted for by the following relations,
ρT = T
∂F (T,C, L | θ)
∂T
, (30a)
ρC = C
∂F (T,C, L | θ)
∂C
, (30b)
with ρT and ρC the dimensionless total TCR and CD8 receptor densities,
respectively. The rescaling, resulting in dimensionless receptor densities,
is performed by the same reference density used to rescale the model pa-
rameters in Sec. 3.3. Next to conservation of total receptor densities, the
total number of ligands is conserved as well. However, as the experiments
were performed under conditions for which the total number of ligands is
in large excess over the total number of available receptors, the number
of ligands in solution, and hence the ligand concentration, is not depleted
irrespective of how many ligands are bound to T cell surface receptors. The
justification of Eqs. (30) is as follows. The binding polynomial tallies the
densities of all model states Xu, and multiplying each state with the cor-
responding number of TCRs respectively CD8 that are within these states
results in the total density of TCRs and CD8, respectively. And this is
precisely what expressions (30) are doing. The numbers of TCR and CD8
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within a model state are given by the exponents of the corresponding re-
ceptors in the state density Xu. The partial derivatives with respect to the
corresponding receptor brings this exponent in front of the state densities,
and multiplication with the receptor density restores the exponent that was
lowered by 1 by the derivative. Hence, Eqs. (30) describe the conservations
of the total TCR and CD8 densities, respectively.
Solving Eqs. (30) on the intervals [0, ρT ], respectively [0, ρC ], for
the both receptor densities T and C yield the densities of unbound TCRs,
T ∗(L | θ), and unbound CD8, C∗(L | θ), in dependence on ligand concen-
tration and model parameters. Evaluating the scaffold expressions (24) for
these values leads to
S∗j (L | θ) := Sj(T ∗(L | θ), C∗(L | θ) | θ) , j = 1, . . . , 4 , (31)
and the density of state u in dependence on ligand concentration and model
parameters is then given by
X∗u(L | θ) := gu · L · κm−1MV
4∏
j=1
S∗j (L | θ)uj . (32)
The observable required in the next chapter is the amount of bound ligands
in dependence on ligand concentration and model parameters, yL(L | θ).
Because every ligand-bound state possesses exactly one ligand, yL(L | θ) is
determined by tallying all ligand-bound states evaluated for state densities
(32),
yL(L |θ) :=
∑
u
X∗u(L | θ)
= L
f∑
m=1
(
ν
m
)
κm−1MV
 4∑
j=1
S∗j (L |θ)
m . (33)
To obtain the amount of bound ligands for the other binding models, the
procedure outlined in this section is carried out the same way but with the
parameters not marked by a cross in Tab. 1 set to zero. In case of Model
B, the affinity K1 has additionally to be rescaled with the factor ε.

4 Identification of pMHC, TCR and CD8 inter-
actions
To elucidate the mechanism by which pMHC interacts with the T cell sur-
face receptors, accurate and quantitative binding data is required. Such
data was provided by the lab of Prof. Dr. Wolfgang Schamel from the Uni-
versity of Freiburg, Germany. All experiments were conducted by Sumit
Deswal. The connection to the modeling framework, outlined in the last
chapter, is made by the conditions under which the experiments were per-
formed. First, T cells were put on ice to prevent incorporation of newly
synthesized receptors into the cell membrane as well as internalization of
cell surface receptors. This assures constant receptor expression throughout
the experiments. Second, the number of T cells was chosen small enough
to guarantee ligand excess over total receptor numbers even at smallest
concentrations. This allows neglecting the depletion of soluble ligands due
to ligand binding. Third, equilibrium binding was established by exposing
the cells to soluble ligands for 2.5 hrs. These three conditions justify the
general framework outlined in Sec. 3.4.
In this chapter, the binding experiments are described and process-
ing of the data is outlined. Then, a statistically-based confrontation of the
interaction models and the data is performed. This leads to the selection of
a best-fitting binding model whose parameters are estimated and assigned
with confidence intervals.
4.1 Binding experiments
The experiments were performed for different experimental conditions given
by the triple
α =
{
cell type, ligand type, tetramer concentration
}
. (34)
33
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Table 2: Receptor expression levels†
The total numbers of TCRs and CD8 co-receptors on T1.CD8- and T1.CD8+ cells were estimated from
triplicate measurements. The results are displayed as mean ± standard error.
† The experiments were conducted by Sumit Deswal in the group of Prof. Dr. Wolfgang Schamel from
the University of Freiburg, Germany.
receptors / cellcell type receptor
TCR
CD8
TCR
CD8
T1.CD8-
T1.CD8+
21 000 400±
1390 10±
17 200 200±
144 000 2000±
Two T cell types, termed T1.CD8- and T1.CD8+, both expressing the same
TCR but differing in CD8 expression levels, were used for data acquisition.
The expression numbers of TCRs and CD8 co-receptors on both cell types
were determined in a separate experiment. The results are shown in Tab.
2. Assuming the same size for both cell types, the expression numbers also
reflect the different receptor densities. As reference density that is used for
parameter rescaling in Sec. 3.3, the TCR density on T1.CD8+ T cells is
employed. The dimensionless receptor densities appearing in Eqs. (30) are
then given by ρT = 1 and ρC = 8.5 for T1.CD8+ T cells, and ρT = 1.2 and
ρC = 0 for T1.CD8- T cells. Hence, the small expression level of CD8 on
T1.CD8- T cells is neglected.
Soluble tetramers, carrying four identical pMHC subunits, served
as ligands. Four different ligand types were used in the experiments. While
the amino acid sequence of the peptides were altered at a single position,
the MHC molecule remained unchanged for each ligand type. Thus, each
kind of pMHC tetramer has distinct affinities to TCR but the same affinity
to CD8. The ligands are referred to as 4L, 4P, 4V, and 4S, and were exposed
to the cells with concentrations ranging from 0.3 nM to 846 nM.
After equilibrium binding was established and before the amount
of bound ligands was detected, it was necessary to remove unspecifically
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Table 3: Dose response binding data†
The recored median fluorescence intensity values obtained by flow cytometry for the different exper-
imental conditions (34). Data was gather for two cell types (T1.CD8- and T1.CD8+), four ligand
types (4L, 4P, 4V, and 4S) and various tetramer concentrations. In total 145 values were measured
distributed over 54 experimental conditions. Triplicates were recorded for 39 conditions, duplicates for
13 conditions and single measurements for 2 conditions. The individual measurement outcomes are
displayed in Fig. 5.
† The experiments were conducted by Sumit Deswal in the group of Prof. Dr. Wolfgang Schamel from
the University of Freiburg, Germany.
tetramer concentration [nM]
cell type ligand type
4L
T1.CD8-
0.04
0.03
0.02
4P
0.3 1 3.3 10 33 100 330 846
0.12
0.09
0.09
0.22
0.16
0.17
0.27
0.22
0.24
0.34
---
0.27
0.41
0.34
0.34
0.53
0.56
---
---
---
---
0.04
0.03
0.02
0.09
0.09
0.07
0.19
0.18
0.14
0.24
0.21
0.20
0.32
0.25
0.24
0.38
0.33
0.32
0.52
0.48
---
0.70
---
---
4V
0.00
0.00
---
0.02
0.02
0.02
0.05
0.05
0.04
0.10
0.10
0.09
0.16
0.15
0.15
0.26
0.24
0.26
0.40
0.39
---
---
---
---
4S
---
---
---
0.00
0.01
---
0.02
0.02
0.01
0.06
0.05
---
---
---
---
---
---
---
---
---
---
---
---
---
4L
T1.CD8+
0.11
0.08
---
4P
0.23
0.17
---
0.36
0.28
0.28
0.54
0.36
0.44
0.80
0.53
0.72
1.06
0.81
1.41
1.47
1.33
---
---
---
---
0.18
0.11
0.11
0.24
0.18
0.21
0.37
0.29
0.31
0.51
0.39
0.42
0.83
0.57
0.64
1.04
0.84
0.97
1.36
---
1.27
1.31
---
---
4V
0.12
0.11
0.11
0.22
0.15
0.19
0.36
0.24
0.28
0.42
0.33
0.43
0.64
0.50
0.67
0.86
0.78
0.95
1.26
1.24
---
---
---
---
4S
0.07
0.06
0.08
0.47
0.55
0.59
0.69
0.83
0.89
1.06
1.06
---
---
---
---
0.15
0.14
0.15
0.27
0.23
0.23
0.31
0.34
0.35
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Figure 5: Dose response binding data†
The detected median fluorescence intensities (MFI) for T1.CD8- (left) and T1.CD8+ (right) cells in
dependence on the concentration of soluble tetramers. For both cell types concentration responses to
4L (brown), 4P (red), 4V (purple), and 4S (blue) ligands were recorded. The circles indicate single
measurements whose values are reported in Table 3. The straight dashed lines connect the respective
mean values.
† The experiments were conducted by Sumit Deswal in the group of Prof. Dr. Wolfgang Schamel from
the University of Freiburg, Germany.
bound ligands from the cells. This so called washing procedure also causes
a loss of a certain amount of receptor-bound ligands. To keep these losses to
a minimum, each pMHC subunit contains a photoreactive 4-azidobenzoic
acid that, upon UV-light radiation, possesses a certain probability to co-
valently cross-link pMHC to the TCR. No such covalent bond is formed
between pMHC and CD8. Only after UV-light exposure, the cells were
washed. The remaining amount of cell-bound tetramers was determined as
median fluorescence intensity (MFI) values by flow cytometry. The result-
ing data is shown in Tab. 3 and Fig. 5.
4.2 Data processing
Reliable outcomes in model selection and parameter estimation require
proper uncertainty assignments to the data. Since these uncertainties are
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unknown in advance, they have to be estimated from the data. MFI val-
ues were measured for 54 different experimental conditions (34). For each
condition, nα repetitive measurements were carried out. The detected MFI
value of the k-th experiment repetition of condition α is denoted by yα,k,
see Tab. 3. It is assumed that the measuring process for each experimental
condition α can be modeled by a normal distribution, i.e.
Yα,k ∼ N (µα, σ2α) , (35)
with Yα,k denoting the random variable describing the measuring process,
µα the true MFI value, and σα the measurement noise. The random vari-
ables of the sample mean, Y¯α, and sample variance, S¯
2
α, for α are given by
Y¯α =
1
nα
nα∑
k=1
Yα,k , (36)
S¯2α =
1
nα − 1
nα∑
k=1
(Yα,k − Y¯α)2 . (37)
For the sample distribution of the mean and the sample distribution of the
variance follows
Y¯α − µα
σα/
√
nα
∼ N (0, 1) , (38)
(nα − 1) S¯2α
σ2α
∼ χ2nα−1 , (39)
with χ2nα−1 the chi-squared distribution with nα − 1 degrees of freedom.
Since the number of repetitions is quite small (nα ≤ 3), error assignment
based on the sample variance is subject to large uncertainties4. There-
fore, an error model including all data is constructed allowing uncertainty
assignments with higher level of precision.
4The mean and variance of χ2nα−1 are given by nα − 1 respectively 2 (nα − 1).
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The error model comprises of a single parameter, the coefficient of
variation ϑ, which is assumed to be independent of α,
ϑ ≡ σα
µα
. (40)
This means that the measurement uncertainty of α is proportional to the
detected signal, and that the proportionality factor – the coefficient of vari-
ation – is common for each experimental condition. Thus, the data of each
α delivers an estimate for ϑ. The corresponding random variable T¯nα is
given by
T¯nα =
S¯α
Y¯α
, (41)
and depends on the number of repetitions nα. Starting from distributions
(38) and (39), the sample distribution of the coefficient of variation, i.e.
the distribution of T¯nα , for nα repetitions, pnα , is determined to be,
pn(t |ϑ) = Cn · tn−2 ·
[
λn(t)
]n
2 ·1F1
(
n
2 ,
1
2 ,
n2 λn(t)
2ϑ2
)
· exp
[
− n
2ϑ2
]
, (42)
λn(t) =
1
n+ (n− 1) t2 ,
Cn =
2
√
n (n− 1)(n−1)/2 · Γ(n2 )√
pi · Γ(n−12 )
,
with 1F1(·, ·, ·) being Kummer’s confluent hypergeometric function defined
by
1F1(a, b, z) :=
Γ(b)
Γ(a) Γ(b− a)
∫ 1
0
ez x xa−1 (1− x)b−a−1 dx ,
and Γ(·) being the Gamma function,
Γ(x) :=
∫ ∞
0
tx−1 e−t dt .
From the sample distribution of the coefficient of variation (42), the log-
likelihood function (5) is computed, serving as starting point for MLE and
the profile likelihood-based confidence interval (see Sec. 2.1 respectively
39 4.2 Data processing
0 0.2 0.4 0.6
0
2
4
6
8
0 0.2 0.4
t t
# 
o
f e
ve
n
ts
n=3n=2
0
2
4
-
2 
(l(ϑ
) -
 
l ma
x)
0.17 0.20.14
A B
ϑ
Figure 6: Error model
(A) Profile likelihood of the error model (black curve). The MLE of the coefficient of variation ϑ is
found to be 0.17. The intersection of the profile likelihood curve and the gray line, located at 3.84,
indicate the lower and upper bounds of the profile likelihood based 95% confidence interval. The value
lmax denotes the maximal value of the log-likelihood function l(ϑ). (B) The binned estimates of the
coefficient of variation (gray bars) and the model predictions (black squares) for n = 2 (left) and n = 3
(right) repetitions.
Sec. 2.3). The results are summarized in Fig. 6. The MLE value ϑˆ
assumes 0.17. The lower and upper bounds of the profile likelihood-based
95 % confidence interval are given by 0.15 and 0.20, respectively (Fig. 6A).
Fig. 6B shows the predicted (black squares) and measured (grey bars)
numbers of values of the coefficient of variation for n = 2 (left) and n = 3
(right) repetitions. The good agreement indicates the plausibility of the
error model.
Having obtained an estimate for the coefficient of variation, assign-
ments to the mean and standard deviation used in model fitting can be
made,
yˆα =
1
nα
nα∑
k=1
yα,k , (43a)
sˆα =
ϑˆ yˆα,n√
nα
. (43b)
In this sense, the measurement uncertainties are taken to be known prior
to model fitting.
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4.3 Washing model
Before coming to model selection and parameter estimation, the washing
procedure has to be taken into account. As described in Sec. 4.1, this is
a two step process. At first, the cells were exposed to UV-light causing
a certain fraction of pMHC-TCR contacts to cross-link covalently. Only
ligands with no such covalent liaison are susceptible to being washed off
in the second step. The incorporation of these steps is at first outlined
for Model A in the following and subsequently generalized to include the
second receptor type CD8.
In order to be detected by flow cytometry, it is sufficient that a
single pMHC subunit of a tetramer remains bound until after the washing
procedure. Therefore, the fraction of ligands loosing all established bonds
is appraised in the following. The probability that a given pMHC-TCR
contact forms no covalent bond upon UV-light exposure is denoted by pUV.
If no such bond is established, the contact may break during the second
washing step, and the chance of this to happen is the higher the weaker the
strength of the bond. This is modeled by relating the strength of a bond –
taken to be reflected by the pMHC-TCR affinity – with a threshold param-
eter KW having the unit of a binding affinity. In particular, it is assumed
that the probability of a given pMHC bond to break can be described by
the following expression,
ploss,1 ≡ pUV KW
KW +K1
. (44a)
It is composed of the independent probabilities pUV and KW/(KW +K1),
with the latter modeling the chance of the pMHC-TCR bond to break dur-
ing the second washing step. The washing loss is the greater the smaller the
affinity is compared to the parameter KW. For a ligand having established
m pMHC-TCR contacts, the fraction of such ligands getting lost during the
washing procedure is given by (ploss,1)
m. Hence, it is assumed that each
bond breaks independently of the others.
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The generalization of the washing model to include CD8 is out-
lined for Model G in the following. As described in Sec. 3.4, each ligand-
bound state of Model G is characterized by a set of four numbers u =
{u1, u2, u3, u4} denoting how many pMHC subunits are bound in which
way to cell surface receptors (see Fig. 4). Only pMHC subunits in di-
rect contact with TCR, i.e. pMHC bound only to TCR as well as pMHC
bound via aggregated state, can benefit from UV-light exposure. To de-
scribe the loss in the second washing step for the different ways pMHC can
be bound to cell surface receptor, expression (44a) is generalized to include
(i) pMHC-CD8 bonds by using K ′1 instead of K1 as affinity, (ii) aggregated
states by rescaling K1 with ξ to account for an impact of adjacent CD8,
and (iii) pMHC bound to the CD8 binding site of TCR-CD8 complex by
using q4K
′
1 instead of K1 to account for binding to CD8 and the impact
of adjacent TCR. In analogy to expression (44a), the probabilities of being
disrupted during the washing procedure for the different pMHC bond types
are taken to be
ploss,2 ≡ KW
KW +K ′1
, (44b)
ploss,3 ≡ pUV KW
KW + ξ K1
, (44c)
ploss,4 ≡ KW
KW + q4K ′1
. (44d)
Also in this case, it is assumed that each bond breaks independently of the
others. A ligand in binding state u has to loose all its u1 + u2 + u3 + u4
bonds with respective probabilities (44) in order to be washed off. At
concentration L and for parameters θ, state u is occupied with density
X∗u(L | θ), defined in (32). The amount of ligands in state u being washed
for these conditions is given by
X˜loss,u(L | θ) :=
4∏
j=1
p
uj
loss,j ·X∗u(L | θ) . (45)
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Using the expression for the state density (32) and exploiting the multi-
nomial theorem once more, the total amount of ligands lost during the
washing procedure is given by
yloss(L |θ) :=
∑
u
X˜loss,u(L | θ)
= L
f∑
m=1
(
ν
m
)
κm−1MV
 4∑
j=1
ploss,j(θ) · S∗j (L |θ)
m. (46)
This expression has to be subtracted from the amount of bound ligands
(33) to obtain the amount of detected ligands,
yD(L |θ) := yB(L |θ)− yloss(L |θ) . (47)
The washing losses for the other models are found by setting those param-
eters to zero that are not marked by a cross in Tab. 1. For Model B the
affinity K1 has further to be replaced by the apparent affinity εK1.
4.4 Model selection and parameter estimation
Having the observable (47) for each model calculated, it can be confronted
with the data (Tab. 3 and Fig. 5) in its processed form (43). The data of
T1.CD8- cells is always described by Model A, while the data of T1.CD8+
cells is interpreted in terms of one of the Models B–G. Since four ligand
types were used, there are four different pMHC-TCR affinities K1,X , with
X = 4L, 4P, 4V, or 4S. Hence, each model recruits its parameters from the
following set of parameters,
θ ∈ {K1,4L, K1,4P, K1,4V, K1,4S, ε, K ′1,
κMV, f, q1, ξ, q4, pUV, KW, M
∗} , (48)
depending on the monomeric binding scheme (Tab. 1), and whether mul-
tivalent binding is possible. The parameter set also comprises of the pa-
rameters used to describe the washing procedure, pUV and KW, as well as
43 4.4 Model selection and parameter estimation
a parameter M∗ denoting a scaling factor relating the predicted amount
of cell-bound ligands to the arbitrary MFI scale of the data. The effec-
tive ligand valency f was not estimated alongside the other parameters.
Instead, for each of the 6 possible binding models for T1.CD8+ cells, it
was set to one of the allowed values 1 to 4. Hence, a total of 24 binding
model-effective valency combinations had to be tested. Importantly, only
the binding affinities K1,X , with X = 4L, 4P, 4V or 4S, depend on the pre-
sented peptide; all other parameters assume a common value for all ligands.
Thus, binding of different ligands is characterized by changing only a single
parameter.
As already assumed in Sec. 4.2, the measuring process for individual
data acquisition follows a normal distribution. Owing the error model, the
estimated means (43a) are also described by a normal distribution with
known standard deviation (43b). Hence, maximum likelihood estimation
is equivalent to least squares estimation (see Sec. 2.2), and the objective
function is given by
χ2(θ) =
∑
α
(
yˆα −M∗ yD,α(θ)
sˆα
)2
. (49)
The concentration dependence of yD(L | θ) has been shifted to the index α
describing the experimental condition (34) yielding the predicted amount
of detected ligand yD,α(θ) depending only on the model parameters θ. The
sum in (49) runs over all experimental conditions meaning that all data is
taken into account at once. The minimization of (49) was performed using
the built-in function lsqnonlin of MATLAB. For each model, the search
was started from at least 1000 different initial conditions. Model selection
was done by exploiting the corrected Akaike Information Criterion and the
quality of the fit was accessed by the goodness-of-fit (see Sec. 2.5 for model
selection and Sec. 2.2 for the goodness-of-fit). The fitting results are sum-
marized in Tab. 4. Based on the corrected Akaike Information Criterion,
Model G with effective ligand valency 2 and 3 are in best agreement with
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Table 4: Fitting Results
The first column denotes the model used to describe the data of T1.CD8+ T cells, and the second
column the effective ligand valency. In total, there are 24 model-effective valency combinations. The
third column shows the number of parameters used to fit the corresponding model including the washing
and scaling parameters. The column with head χ2min gives the value of the objective function (49)
obtained at MLE values of the parameters. The goodness-of-fit (gof, see Eq. (11)) is displayed in the
fifth column. Finally, the difference of the corrected Akaike Information criterion (∆AICc, see Sec.
2.5) is shown in the last column. The gray frame surrounding Model G with effective ligand valencies
of 2 and 3 indicates that these two models are in best agreement with the data, while all other models
were ruled out according to ∆AICc > 10 [8].
# of parametersmodel effective valency
1
B
8
9
9
928
723
586
20.2
16.1
13.0
9 534 11.9
χ2
min
2
3
4
1
C
8
9
9
9
2
3
4
1
D
9
10
10
10
2
3
4
1
E
9
10
10
10
2
3
4
1
F
10
11
11
11
2
3
4
1
G
11
12
12
12
2
3
4
280
219
195
189
270
183
147
137
270
183
147
137
192
123
99
91
104
62
67
79
6.1
4.9
4.3
4.2
6.0
4.2
3.3
3.1
6.0
4.2
3.3
3.1
4.4
2.9
2.3
2.1
2.4
1.5
1.6
1.9
853
651
514
462
ΔAIC
c
206
147
123
117
198
114
78
68
198
114
78
68
123
57
33
25
38
0
5
16
gof
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Figure 7: Data fit of Model G3
The measured median fluorescence intensities (dots) and the model fits (full lines) in dependence on
tetramer concentration are displayed. The top row shows T1.CD8- and the bottom row T1.CD8+ cells.
The different ligand types are indicated by color: 4L in brown, 4P in red, 4V in purple, and 4S in blue.
The shaded areas describe the standard deviation of single measurements as estimated from the error
model.
the data. All other models were ruled out according to ∆AICc > 10 [8].
The gof of Models G2 and G3 are 1.5, respectively 1.6, indicating that
the data is well described by both models. It is generally believed that
tetramers can engage up to three pMHC simultaneously [85], i.e. f = 3.
Hence, Model G3 is further discussed in the following. The results of Model
G2 can be found in Appendix A. The performance of Model G3 on the data
is depicted in Fig. 7 showing that the data is well captured by the model.
The uncertainties in the estimated parameter values in terms of
95% confidence intervals were calculated by the profile likelihood method
(see Sec. 2.3). The profile likelihood curves are shown in Fig. 8A. All
parameters, except for q1, ξ and pUV, are completely identifiable, i.e. they
have an upper and lower bound. While q1 and ξ have at least an upper
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Figure 8: Profile likelihoods of Model G3
(A) The profile likelihood curves (black) of the 12 parameters used for fitting Model G3. The intersec-
tions of the profile likelihood curves with the gray lines, located at ∆χ2 = 3.84, define the independent
95 % confidence intervals of the model parameters. (B) Prediction profile likelihood of TpC4P,10 nM, the
fraction of TCRs in aggregated state for the 4P ligand at a concentration of 10 nM. The gray line plays
the same role as in (A).
bound, pUV could not be determined. Thus, the model parameters are well
constraint by the data. The best-fit parameters θMLE, and the lower and
upper bounds of the 95 % confidence intervals, θlow respectively θup, are
shown in Tab. 5. The estimated dissociation constants – the inverses of
the binding affinities – lie between 0.25 µM and 5 µM for the 4L and 4P
ligand, between 0.5 µM and 10 µM for the 4V ligand, between 10 µM and
100 µM for the 4S ligand, and between 3 µM and 100 µM for CD8 binding to
pMHC. These values are in good agreement with previous reports of pMHC-
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Table 5: Parameter values of Model G3
The maximum likelihood estimations θMLE, and the lower and upper bounds of the profile likelihood-
based 95 % confidence intervals, θlow and θup, of the 12 parameters used for fitting Model G3 are shown.
The last column gives the values θ∗ obtained by prediction profile likelihood as described in the main
text. These values are assigned to the parameters of Model G3.
parameter
K
1,4L
 [µM-1]
κ
MV
 [µM]
θ
MLE
θ
low
θ
up
θ*
q
1
q
4
ξ
p
UV
M*
K
1,4P
 [µM-1]
K
1,4V
 [µM-1]
K
1,4S
 [µM-1]
K’
1
 [µM-1]
K
W
 [µM-1]
0.9 0.2 4 1.1
0.9 0.2 4 1.1
0.4 0.1 2 0.5
0.03 0.01 0.1 0.03
0.05 0.01 0.3 0.06
6 0.7 45 4.7
0 0 3 0.18
0 0 3 0.18
3.3 2.2 80 6.9
0 0 1 0
1.0 0.8 1.3 1.0
0.06 0.002 0.7 0.09
TCR affinities [18] and murine MHC-CD8 affinity [30]. The multivalent
engagement parameter κMV is estimated lie between 0.7 µM and 45 µM.
This value is an indicator for the capability of a ligand to form multivalent
binding states. Ligands with dissociation constants larger than κMV hardly
bind multivalently. In case of the cognate 4P ligand, the MLE value of
the dimensionless association constant of multivalent binding, κMVK1,4P
assumes a value of about 5. This is in good agreement with previously
reported values on such dimensionless multivalent binding constants [35,
23, 73]. The accordance of the estimated affinities and multivalent binding
parameters with the literature is further evidence on the plausibility of the
model and its underlying assumptions.
The association constant for pMHC-independent TCR-CD8 com-
plex formation q1 is zero for the best fit and has an upper bound of 3.
Thus, up to 95 % of the TCRs on T1.CD8+ cells might be bound to CD8
in the absence of ligands. However, because of this large uncertainty and
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due to the fact that this value also depends on the relative expression level
of CD8 compared to TCR, a clear estimate of the fraction of TCRs in
TCR-CD8 complexes in the absence of ligands cannot be made. A striking
finding is that q4, the association constant of TCR-CD8 complex forma-
tion if pMHC is bound to CD8, is significantly larger than q1. This means
that pMHC-bound CD8 has an increased ability to bind TCR compared
to CD8 alone, or, put equivalently, the affinity of pMHC binding to CD8
is enhanced if CD8 is bound to a TCR. A similar effect is not observed
for pMHC-bound TCRs. As ξ is very similar to q1, an enhancing impact
for pMHC-TCR binding if CD8 is bound to the TCR, or pMHC binding
to the TCR binding site of a TCR-CD8 complex, is – if present at all –
very small. The probability to not form a covalent bond between a pMHC-
TCR contact upon UV-light irradiation, pUV, could not be determined. A
reason might be that, in the concentration range used for data acquisition,
multivalent binding dominates over monovalent binding – at least for the
4L, 4P, and 4V ligand. Multivalently bound ligands have a better chance
to survive cell washing as rebinding of a ligand subunit is possible before
all other subunits loose contact [85], and hence UV-light induced cross-
linking of pMHC and TCR might not be too relevant. The estimated value
of the washing parameter KW indicates that substantial washing loses are
expected for the weak binding 4S ligand as well as for pMHC-CD8 bonds.
The higher affinity ligands are less impacted by the washing step. Finally,
the scaling factor M∗ assumes a value of 1. This was expected as the MFI
scale in Fig. 5 is of that order of magnitude.
For the further discussion of Model G3, it is convenient to not use
θMLE, since the parameter ξ is zero (Tab. 5). As ξ describes the formation
of aggregated states, i.e. TCRs in direct contact with pMHC and adjacent
CD8, it is of particular biological interest, and also plays a central role
in the subsequent chapters. To find a parameter set, on the one hand in
agreement with the data, and on the other hand allowing for the forma-
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tion of aggregated states, the method of prediction profile likelihoods was
exploited (see Sec. 2.4). As prediction, i.e. as quantity deviated from its
MLE value, the fraction of TCRs in aggregated state that establishes for
the 4P ligand at 10 nM concentration (TpC4P,10 nM) was chosen. The pre-
diction profile likelihood curve is shown in Fig. 8B. The parameter set θ∗,
obtained at ∆χ2 = 2, is given in the last column of Tab. 5, and henceforth
used to parameterize Model G3.

5 Competition binding model
This section focuses on the discussion of Model G that from here on is
termed Competition Binding Model (CBM) for reasons that will become
clear later on. The parameterization of CBM is given by the parameter
set θ∗, see the last column of Tab. 5. All possible binding states of CBM
for soluble tetramer with effective valency f = 3 are shown in Fig. 4. In
this setup, the impact of CD8 on ligand binding and receptor occupancy is
investigated, and multivalent binding is considered as predictor for T cell
activation.
5.1 Ligand binding and receptor occupancy
In CBM, each pMHC subunit is bound according to one of four possibilities;
three of which involve TCRs. The corresponding fractions of TCRs in
dependence on ligand concentration with respective pMHC contacts are
given by
yTp(L) :=
∑
u
u1X
∗
u(L |θ∗) , (50a)
yTpC(L) :=
∑
u
u3X
∗
u(L |θ∗) , (50b)
yTCp(L) :=
∑
u
u4X
∗
u(L |θ∗) , (50c)
where the sums run over all binding states u. Expression (50a) denotes the
fraction of TCRs bound only to pMHC, because X∗u(L |θ∗) is the density of
binding state u in dependence on ligand concentration (32) evaluated for
parameters θ∗, and u1 is the number of pMHC-TCR bonds in that binding
state. Likewise, yTpC is the fraction of TCRs in aggregated states, and
yTCp the fraction of TCRs in TCR-CD8 complexes to which pMHC is only
bound to the CD8 subunit.
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The curve progressions of these fractions as well as their total in
dependence on ligand concentration for the 4P, 4V, and 4S ligands are
shown in Fig. 9A. The totals are very similar irrespective of the strength
of pMHC-TCR binding (full curves). This property is also reflected in the
binding data of T1.CD8+ cells (Fig. 5). However, the composition of the
totals exhibit great differences between the different ligands. For concentra-
tions less than 1000 nM, the 4S ligand, which has a pMHC-TCR affinity of
0.03 µM−1, binds almost exclusively to the CD8 binding site of TCR-CD8
complexes (blue dotted curve) and barely to TCRs directly (blue dashed
and blue dashed-dotted curves). Thus, in this concentration range, binding
of the weak 4S ligand is dominated by ligand-unspecific interactions. At
concentrations larger than 1000 nM, direct contacts between pMHC and
TCRs (yTp) emerge, which is accompanied by the decline of interactions
of pMHC with the CD8 binding site of TCR-CD8 complexes. The rea-
son for this behavior is that at such large concentrations, each receptor
preferentially binds its own ligand rather than sharing one, as it is the
case for the TCR-CD8 complex. This is the same argument explaining the
bell-shaped curve of bivalent binding in Fig. 1. Thus, it is only at very
large concentrations that low affinity ligands can bind TCRs directly, as
otherwise the CD8 binding site of TCR-CD8 complexes offers a strong and
ligand-unspecific competitor. This competition property is what gives the
name to CBM. Note that at no concentration value appreciable amounts
of aggregated states are formed.
The ligands 4P and 4V, having pMHC-TCR affinities of 1.1 µM−1,
respectively 0.5 µM−1, manage to form direct contacts between pMHC and
TCRs. This includes TCRs binding pMHC alone (dashed curves), as well
as aggregated states (dash-dotted curves). Importantly, the higher the
pMHC-TCR affinity the more such bonds form. This coincides with less
pMHC binding to the CD8 binding site of TCR-CD8 complexes (dotted
curves). Thus, high affinity ligands are able to counteract the strong and
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Figure 9: Receptor occupancy for CBM
(A) Fraction of TCRs bound according to the different interaction possibilities of CBM for the 4P
(red), 4V (purple) and 4S (blue) ligands in dependence on ligand concentration. The dashed lines show
TCRs bound to pMHC alone, the dash-dotted lines TCRs in aggregated state, the dotted lines TCRs
in TCR-CD8 complexes to which pMHC is bound to the CD8 binding site, and the full lines the total
of the three. (B) Impact of CD8 on the fraction of TCRs in direct contact with pMHC in dependence
on ligand concentration using the same ligands and color code as in (A). The full lines show binding
for T1.CD8+ cells and the dashed lines for T1.CD8- cells.
ligand-unspecific interactions with the CD8 binding site of TCR-CD8 com-
plexes showing that despite similar total binding, ligand-specific binding
is manifested in CBM. The decline of pMHC bonds with TCR-CD8 com-
plexes, i.e. yTpC and yTCp, at high concentration has the same reason as
above; each ligand prefers binding its own receptor.
The finding that total binding is very similar for all ligands, but
the individual contributions are distinct can be understood qualitatively
in the framework of a toy model of CBM. Assume a receptor possessing
two binding sites; one for productive and one for unproductive binding.
Importantly, only one of the two binding sites can be bound simultaneously.
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The productive binding site is supposed to reflect binding in which pMHC is
in direct contact with a TCR, i.e. yTp and yTpC, while unproductive binding
mirrors binding to the CD8 binding site of the TCR-CD8 complex yTCp.
The affinity of a (monovalent) ligand for productive binding is denominated
with KP and depends on ligand quality, while the affinity of unproductive
binding, termed KU , is independent thereof. Unproductive binding is of
high affinity; i.e. it holds KP ≤ KU . In particular, for ligands with low
productive affinity one has KP  KU , while ligands with high productive
affinity fulfill KP ≈ KU .The fraction of occupied receptors (total binding),
is given by
ytotal ≡ (KP +KU )L
1 + (KP +KU )L
≈

2KU L
1 + 2KU L
if KP ≈ KU ,
KU L
1 +KU L
if KP  KU .
(51)
Thus, total binding is very similar for all ligands independent of their ability
to bind productively, as the overall affinity KP + KU differs at most by a
factor of 2 between different affinity ligands. Nevertheless, the fraction of
productively bound ligands, given by
yprod ≡ KP L
1 + (KP +KU )L
≤ KP
KP +KU
, (52)
shows a distinct dependence on affinity KP . For ligands with low produc-
tive affinity, a proportion of at most KP /KU  1 receptors are bound
productively. On the other hand, high affinity ligands can achieve a non-
zero fraction of productive interactions. This shows how the existence of
a TCR-CD8 complex with a ligand-unspecific high affinity binding site ex-
plains the great similarity in ligand binding observed, while the ability to
distinguish between different pMHC-TCR affinity ligands is maintained.
The impact of CD8 on direct pMHC-TCR binding is shown in Fig.
9B. In general, on T1.CD8+ cells, more bonds between pMHC and TCR
are formed at lower concentrations than on T1.CD8- cells, and fewer at
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higher concentrations. The points of intersection, however, depend on lig-
and affinity. The lower the affinity the higher the concentration value, and
the smaller the fraction of pMHC-bound TCRs at the intercept. Due to
this property, the fraction of TCRs in direct contact with pMHC for the
4S ligand remains at a relatively low level much longer than in the absence
of CD8. Additionally, high affinity ligands achieve a substantially higher
degree of direct pMHC-TCR contacts at low concentrations in the presence
of CD8. Because foreign (high affinity) antigen is expected to be presented
at relatively low doses while self (low affinity) peptides are presented at
rather high doses, this finding suggests that CBM possesses the capability
to detect foreign antigen with greater sensitivity, and to improve self tol-
erance, i.e. the ability not not respond to self peptides, if CD8 is present.
However, because all ligands eventually reach full occupancy independent
of ligand affinity and CD8 expression, low affinity can be compensated by
high dose offering the possibility to compromise ligand discrimination.
5.2 Multivalent binding and TCR activity
As pointed out in Sec. 1.1, multivalent engagement, in contrast to receptor
occupancy, allows for affinity-based ligand discrimination and T cell acti-
vation if T cells are probed with soluble ligands. Therefore, multivalent
binding of CBM is investigated in the following. In the absence of CD8,
CBM reduces to Model A, which comprises only of the states {m, 0, 0, 0},
with m assuming the values 1 to 3 (see Fig. 4). All states obeying m ≥ 2,
i.e. all states in which a ligand binds at least two TCRs simultaneously,
are referred to as signaling competent states, and each TCR in such states
is regarded as a signaling TCR. As has been shown by Perelson [59], mul-
tivalent binding curves in dependence on ligand concentration, established
by oligomers with valency ν and effective valency f ≥ 2, are bell-shaped
(see Fig. 1), and have a single maximum located at concentration value
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Lpot given by
Lpot ≡

1
ν K1
if κMVK1  1,
1
(f − 1) ν K1 if κMVK1  1.
(53)
The (dimensionless) parameter κMVK1 assumes the values 5.2, 2.4, and
0.1 for the 4P, 4V, and 4S ligand, respectively, indicating that Lpot lies
between 110 nM to 230 nM for 4P ligand, 250 nM to 500 nM for the 4V
ligand, and 4200 nM to 8300 nM for the 4S ligand, with the latter expected
to be at the upper bound due to the smallness of κMVK1. The fractions
of signaling TCRs for the 4P, 4V, and 4S ligand in dependence on ligand
concentration are shown in Fig. 10A confirming the afore mentioned. Ow-
ing the assumption of a uniform multivalent binding parameter κMV, high
affinity ligands induce signaling at lower concentrations than low affinity
ligands, and the maximal amount of signaling TCRs increases with ligand
affinity [75]. Considering a model of T cell activation that requires a mini-
mal number of signaling TCRs in order to trigger a T cell, ligands with too
low affinity are incapable of activating T cells as they fail to establish this
minimal number of signaling TCRs. Hence, multivalent engagement allows
for affinity-based ligand discrimination.
In the following, these arguments are generalized to CBM, and it
is investigated whether in this case affinity-based ligand discrimination is
still possible, and how the influence of CD8 is manifested. CBM com-
prises of 3 bivalent and 10 trivalent ligand-bound states that contain at
least two TCRs in direct contact with pMHC. Each TCR in such a state
that is in direct contact with pMHC is regarded as a signaling TCR (in-
dicated by subjacent arrows in Fig. 4). These TCRs are divided into two
groups: weak signaling TCRs (thin arrows) and strong signaling TCRs
(thick arrows). Strong signaling TCRs have an adjacent CD8 co-receptor
(aggregated state) while weak signaling TCRs lacking it. The reason for
this nomenclature is that CD8 recruits the kinase Lck to the TCR [83, 79].
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Figure 10: Signaling TCRs for CBM
Fraction of signaling TCRs in dependence on ligand concentration for the 4P, 4V, and 4S ligand as
indicated by color. (A) In the absence of CD8. (B) With CD8. Dashed lines show strong signaling
TCRs, yss, dashed-dotted lines weak signaling TCRs, yws, and the full lines all signaling TCRs, yws+yss.
Using the notation introduced in Sec. 3.4, the proportions of weak signaling
TCRs, yws, respectively strong signaling TCRs, yss, are given by
yws(L) :=
∑
u
u1+u3≥2
u1X
∗
u(L |θ∗) , (54)
yss(L) :=
∑
u
u1+u3≥2
u3X
∗
u(L |θ∗) . (55)
The sum runs over all binding states u that contain at least to TCRs in
direct contact with pMHC, i.e. pMHC-TCR (u1) or aggregated state (u3).
The total fraction of signaling TCRs in dependence on ligand concentration
is given by the full lines in Fig. 10B for the 4P, 4V, and 4S ligand. As
for T1.CD8- cells, the higher the affinity the earlier signaling TCRs emerge
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and the larger the maximal number of signaling TCRs becomes. Thus,
affinity-based ligand discrimination is also possible in the presence of CD8.
However, there are notable differences between the presence and absence
of CD8. To begin with, in the presence of CD8, fewer TCRs are bound
appropriate for signaling than without CD8 (compare full lines in Figs.
10A and B). The reason is that CBM comprises of several multivalent TCR
binding states that are not signaling competent (see Fig. 4). Especially
states in which a pMHC subunit is bound to the CD8 binding site of a
TCR-CD8 complex (yTCp in Fig. 9A) are prominently occupied leading to a
depleted availability of TCRs able of forming a signaling competent state. A
further difference is that, for T1.CD8+ cells, the total fractions of signaling
TCRs are bimodal functions of ligand concentration. The total fraction of
signaling TCRs is composed of weak and strong signaling TCRs (dashed
and dash-dotted lines in Fig. 10B). As outlined in Sec. 5.1, simultaneous
binding of pMHC to TCR and CD8, as in binding states with u3 or u4 > 0,
disappears at high concentrations. Thus, TCRs from states with u4 >
0, which are not signaling, are released allowing the formation of states
containing weak signaling TCRs (dash-dotted lines in Fig. 10B). This is
especially pronounced for low affinity ligands, because for those, pMHC
binding is dominated by binding to the CD8 binding site of TCR-CD8
complex. Hence, a second peak is formed at high concentrations, which is
the more evident the lower the affinity.
Despite the finding that fewer signaling TCRs are established for
T1.CD8+ cells, it does not compulsorily result in diminished T cell activa-
tion. Among the signaling TCRs of CBM, strong signaling TCRs (dashed
lines in Fig. 10B) are expected to be more potent than weak signaling
TCRs due to the ability of CD8 to recruit the kinase Lck to the TCR. This
leads to the concept of TCR activity, which denotes the overall intracellular
signal intensity established in response to ligand encounter. The following
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simple model for TCR activity is considered
yws
η←→ y∗ws , (56a)
yss
ψ η←→ y∗ss . (56b)
The asterisk denotes the active state of weak and strong signaling TCRs.
The parameter η describes the signal intensity a weak signaling TCR es-
tablishes. The impact of CD8 on the signaling capacity of a TCR is simply
modeled by an enhancement factor ψ > 1. The TCR activity in dependence
on ligand concentration is now defined as
yact(L,ψ) := y
∗
ws(L) + y
∗
ss(L)
= η
[
yws(L) + ψ yss(L)
]
, (57)
and describes the overall signal emanating from signaling TCRs. In princi-
ple, the parameter η can depend on ligand properties. For example, kinetic
proofreading predicts a dependence on the rate of pMHC-TCR dissociation
[49]. However, no such dependencies are considered in the remainder of this
work. Therefore, η reduces to a simple scaling factor and is thus set to one,
η ≡ 1. Note that this implies that the TCR activity in case of T1.CD8-
cells is identical to the proportion of signaling TCRs.
From Fig. 10, it becomes apparent that strong signaling TCRs for
T1.CD8+ cells have a peak at lower concentrations than signaling TCRs
for T1.CD8- cells. Thus, for sufficiently large values of ψ, a given ligand
can induce a larger TCR activity at smaller concentrations for T1.CD8+
cells than for T1.CD8- cells leading to an increased sensitivity for that
ligand in the presence of CD8. Such an increase in TCR activity, as de-
sired it might be for high affinity, i.e. foreign, ligands, could also lower
self tolerance, because low affinity, i.e. self, ligands experience the same
CD8-related enhancement effect. However, the peak value of the strong
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signaling TCRs of the 4S ligand for T1.CD8+ cells is almost 3 orders of
magnitude smaller than the peak value for T1.CD8- cells, while for the 4P
ligand, it is only 1 order of magnitude. Hence, there is a window of values
for ψ in which TCR activity is increased for high affinity ligands in the
presence of CD8 while TCR activity remains suppressed for low affinity
ligands. These findings are striking as they suggest that CBM exhibits the
capability of sensing small amounts of foreign, i.e. high affinity, antigen
more sensitively than CD8 negative T cells and additionally tolerating self,
i.e. low affinity, peptides with higher specificity. This means that the usual
trade-off between sensitivity and specificity, i.e. gaining one reduces the
other, is not encountered.
To quantify this observation, two measures for a ligand’s ability to
activate T cells are introduced – termed potency and efficacy. In contrast to
their usual definitions, efficacy yeff is defined to be the maximal TCR activ-
ity a ligand can establish, and potency Lpot is defined as the concentration
at which maximal TCR activity is reached,
yeff(ρC , ψ) := max
L
yact(L,ψ) . (58a)
Lpot(ρC , ψ) := arg max
L
yact(L,ψ) . (58b)
The rationale behind these definitions is the assumption that a minimal
TCR activity is needed in order to trigger T cell activation. Expression
(58a) determines whether this minimal TCR activity can be established by
a given ligand that causes a TCR activity yact, and expression (58b) gives
the dose at which the ligand induces optimal TCR activity. The unit of the
efficacy is such that it equals 1 if all TCRs on a T cell are weak signaling
and ψ if all TCRs are strong signaling. The definition of the potency (58b)
is such that it yields expression (53) if T cells lack CD8. Next to the
dependence on the enhancement factor ψ, efficacy and potency are chosen
to be further depend on the CD8 expression level ρC . This dependence
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Figure 11: Efficacy and potency of CBM for soluble ligands
(A) Ligand efficacy in dependence on enhancement factor ψ for 4P, 4V, and 4S ligand as indicated by
color. Dashed lines represent T1.CD8- cells and full curves T1.CD8+ cells having ρC = 8.5. (B) Ligand
efficacy in dependence on the relative CD8 expression level ρC for 4P, 4V, and 4S ligand as indicated
by color and ψ = 100. (C) Same as (B), but potency Lpot versus ρC is shown.
is inherited from the TCR activity as it depends on ρC via the weak and
strong signaling TCRs.
The efficacy in dependence on enhancement factor ψ for 4P, 4V, and
4S ligand is shown in Fig. 11A. In the absence of CD8 (dashed lines), there
is of course no dependence of the efficacy on ψ, and the efficacy assumes
the peak value of signaling TCRs given in Fig. 10A of the corresponding
ligand. For T1.CD8+ cells, having an CD8 expression level of ρC = 8.5,
the efficacy increases almost linearly with ψ for 4P and 4V ligand. For the
4S ligand, a linear increase sets in at ψ > 10 while the efficacy stays almost
constant below. The reason is that, for 4S ligand, the peak value of strong
signaling TCRs is 1 order of magnitude smaller than the peak value of weak
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signaling TCRs (see Fig. 10B). Thus, efficacy is almost exclusively given
by weak signaling TCRs if ψ < 10, whereas for ψ > 10, strong signaling
TCRs dominate efficacy leading to the linear increase. The value of ψ at
which the efficacies of T1.CD8- and T1.CD8+ cells become equal depends
on ligand affinity. It is given by 8, 21, and 530 for 4P, 4V, and 4S ligand,
respectively. Hence, there is indeed a window of values for ψ in which high
affinity ligands benefit from the CD8-related enhancement of TCR activity,
while low affinity ligands fail to become more efficacious due to interactions
of pMHC with the CD8 binding site of TCR-CD8 complexes.
Next, the impact of CD8 expression level is investigated. The en-
hancement factor is set to ψ = 100 yielding an increased efficacy for 4P and
4V ligand as well as lowered efficacy for 4S ligand at CD8 expression level
ρC = 8.5 compared to ρC = 0. As shown in Fig. 11B, the beneficial effect
of CD8 on 4P and 4V ligand sets in immediately and is most pronounced at
ρC ≈ 4 and ρC ≈ 2 for 4P and 4V ligand, respectively. For larger values a
slight decrease is found. For the 4S ligand, the efficacy remains almost con-
stant until ρC ≈ 1 and starts to decrease for larger values of ρC . Hence, for
ψ = 100, CD8 exhibits the respective beneficial effects concerning efficacy
on both, high and low affinity ligands, for CD8 expression levels ρC > 1.
Not only the amount of TCR activity is important but also which
ligand dose elicits it. Therefore, the potency in dependence on CD8 expres-
sion level for ψ = 100 is considered. As shown in Fig. 11C, the potency is
a decreasing function of ρC for all ligands. At ρC = 0, the potency is given
by (53), and hence, is as distinct as the ligand affinities. This means that
high affinity ligands are optimally sensed at low concentrations, whereas
the potency of low affinity ligands is found at high concentrations. With
increasing ρC , the potencies become more and more similar indicating that
the maximal TCR activity is established at rather small concentration val-
ues for all ligands. As a consequence, smaller doses of high affinity ligands
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4P and 4V can be sensed in the presence of CD8. This is of great relevance
as foreign antigen is expected to be presented with minute amounts. The
decrease of potency for the 4S ligand has also beneficial effect, because the
rather large amounts with which low affinity self peptides are presented are
suboptimal, which further improves self tolerance.
In summary, CBM possesses a TCR-CD8 complex that binds pMHC
with high affinity only with its CD8 binding site independent of peptide
quality, which is in competition with signal-inducing pMHC-TCR engage-
ment. A further contribution of CD8 arises from the recruitment of kinase
Lck leading to an increased TCR activity for pMHC-TCR-CD8 complexes
in which pMHC is in direct contact with the TCR. Hence, CD8 plays a
dual role in CBM. On the one hand, it prevents the formation of signaling
competent TCRs, and on the other hand enables enhanced signaling once
such signaling TCRs have formed. Whether a ligand benefits from signal
enhancement or suffers from diminished pMHC-TCR binding depends on
the ligand affinity. High affinity ligands are able to counteract the peptide-
independent high affinity interaction leading to enhanced signaling in the
presence of CD8. Furthermore, the optimal dose of T cell stimulation is
also reduced with CD8 leading to increased sensitivity towards high affinity
antigens. Low affinity ligands, on the other hand, fail to establish signal-
ing competent TCRs as they cannot counteract the peptide independent
high affinity interaction. Moreover, CD8 related enhancement effects are
expected to deploy at small concentrations, and self peptides, usually of
low affinity and presented at high doses, would hardly benefit from them.
Thus, as self peptides are not supposed to trigger T cell activation, the
contribution of CD8 leads to increased self tolerance. Taken together, the
findings indicate that the presence of CD8 enhances sensitivity towards for-
eign antigens as well as self tolerance in response to self peptides assigning
CD8 an important role in ligand discrimination and T cell activation.
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5.3 Comparison to experiment
The analysis of the preceding section gives rise to four testable predictions.
First, the dose response curves of T cell activation are bell-shaped. This
is a consequence of the notion that TCR activity is triggered by multiva-
lent binding rather than receptor occupancy. Second, the higher the lig-
and affinity the more signaling competent TCRs are formed, and the more
TCR activity is established. This prediction results from the assumption
of a uniform multivalent engagement parameter (see Sec. 3.2). Third, CD8
increases TCR activity only for higher affinity ligands. This reflects the
impact of enhancement factor ψ on TCR activity. And fourth, for a given
ligand, the potency is the lower the larger the CD8 expression level. Im-
portantly, none of the stated predictions are specific for CBM. The first
two predictions make general statements about multivalent binding, and
how it is incorporated in the general modeling concept outlined in Sec. 3.2.
The third prediction is also made by any model allowing for simultaneous
binding of TCR and CD8 to the same pMHC, i.e. Models D, E, and F,
because a similar model of TCR activity can be applied. And lastly, the
dependence of the potency on ρC is also expected for these other models.
Take Model D (see Chap. 3) as example. Next to binding of pMHC to TCR
with concentration-rescaled affinity K1L, TCR can also bind CD8-bound
pMHC with effective association constant K ′2C · K1L. Thus, binding of
pMHC to TCR is described by an apparent affinity (1 + K ′2C)K1 > K1.
Following Eq. (53), a shift in potency towards smaller values in depen-
dence on CD8 expression level is expected as well. This shows that the
predictions make general statements about the underlying modeling con-
cepts rather than a specific remark on CBM that no other model makes.
One such CBM-specific prediction, for which, however, no data is at hand,
is to prevent Lck to bind to CD8 and thereby extinguish the enhancement
effect of CD8 on TCR activity. CBM predicts in this situation that even
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high affinity ligands exhibit the lesser TCR activity, and hence the lesser
ability to trigger T cell activation, the larger the CD8 expression level. As
in no other model CD8 inhibits pMHC-TCR binding, this prediction is
specific for CBM.
To test for the four stated predictions above, T cell activation in-
duced by soluble tetramers was detected as changes in expression level of
the T cell surface marker CD69 [78, 17]. All experiments, including the ones
described further below, were performed by Sumit Deswal in the group of
Prof. Dr. Wolfgang Schamel from the University of Freiburg, Germany.
T1.CD8- and T1.CD8+ cells were exposed to different concentrations of
4P, 4V, and 4S ligand, and the CD69 expression level was measured after
12 hours. Assuming that CD69 up-regulation is a strictly increasing func-
tion of TCR activity, the concentration dependence of CD69 up-regulation
follows the qualitative progression of TCR activity. Thus, observed peaks
in CD69 up-regulation coincide with a ligand’s potency. However, the ex-
periments were performed at 37 ◦C; by contrast, the binding measurements
were performed at 4 ◦C. This means that temperature dependencies of
the model parameters might interfere with the predictions. In particular,
pMHC-TCR binding affinities have been observed to decline with increas-
ing temperature [54, 72]. As a consequence, T cell activation curves are
expected to be shifted towards larger concentration values by an amount
that depends on the CD8 expressing level (see Fig. 11C).
The results of the measurements of CD69 up-regulation as means
of T cell activation are shown in Fig. 12A and B. The amount of de-
tected CD69 follows a bell-shaped curve strongly pointing towards mul-
tivalent binding as origin of T cell activation. Further, a clear hierarchy
with pMHC-TCR affinities is observed. Moreover, the 4P and 4V ligand
are more efficacious on T1.CD8+ cells than on T1.CD8- cells. Also the
4V ligand induces more CD69 expression on T1.CD8+ cells than the 4P
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Figure 12: T cell activation data†
(A) CD69 up-regulation in dependence on tetramer concentration for 4P, 4V, and 4S ligands as indicated
by color for T1.CD8- cells measured at 37 ◦C. The dots denote mean values, and the error bars standard
errors of 3 experiment repetitions. The dashed lines are straight connectors of the mean values. The
black line shows the background MFI in the absence of ligands. (B) Same as (A) but for T1.CD8+
cells having a CD8 expression level of ρC = 8.5. (C) Conformational change of the TCR determined
by SH3.1 (Nck) pull down assay in response to 4P ligand for T1.CD8- cells measured at 4 ◦C. Dots
represent means, and error bars standard errors of 3 experiment repetitions. The dashed line connects
the mean values. (D) Calcium influx over time for OT-1 cells for various concentrations of OVA ligand
as indicated measured at 37 ◦C.
† All experiments were performed by Sumit Deswal in the group of Prof. Dr. Wolfgang Schamel of the
University of Freiburg, Germany.
ligand on T1.CD8- cells. The 4S ligand fails to trigger CD69 up-regulation
on both cell types. This indicates that the value of ψ = 100 chosen in Fig.
11B and C is reasonable. Taken together, these observations confirm the
first three predictions made above. However, a CD8 dependence of the po-
tency is not found. The predicted potencies at 4 ◦C of 4P and 4V ligand for
T1.CD8+ cells (ρC = 8.5) are 3 nM and 4 nM, respectively (see Fig. 11C).
As the potency depends only weakly on affinity for high CD8 expression
levels, the predicted potencies should also be valid at 37 ◦C. Indeed, the
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peaks of CD69 up-regulation for T1.CD8+ cells are found at about 10 nM
in good agreement with the predictions. The potencies at 4 ◦C of 4P and
4V ligand for T1.CD8- cells are predicted to be 160 nM and 390 nM, respec-
tively. Without CD8, the potency depends on the affinity K1 according to
∼ 1/K1. Hence, the predictions give a lower bound on the concentration
value of the peak of CD69 up-regulation if affinities decline with tempera-
ture. However, the measured peak values are 5 nM and 10 nM for 4P and
4V ligand, respectively, exhibiting a poor agreement with the predictions.
Indeed, no dependence of the potency on CD8 expression level was found
in the experiment in contradiction with the fourth prediction.
To have a closer look at T cell activation of T1.CD8- cells, the con-
formational change of the TCR by a SH3.1 (Nck) pull down assay [31, 51]
was measured. Importantly, these measurements were performed under
the exact same conditions as the dose response binding data, and hence, no
temperature effects are expected. The detected conformational change in-
duced by 4P ligand is shown in Fig. 12C. The measured peak value, located
at about 100 nM, is in good agreement with the prediction of 160 nM. How-
ever, similar data for the other ligands and T1.CD8+ cells are not available.
The finding of the measurement of TCR conformational change in-
dicates that the potency might exhibit a dependence on CD8 expression
level. To further consider this possibility, T cell activation by means of cal-
cium influx for OT-1 cells in response to OVA ligand – the cognate ligand
of OT-1 cells – has been recorded at 37 ◦C. The measured time courses for
various concentrations of OVA ligand is shown in Fig. 12D. One finds that
calcium influx is maximal at concentrations of about 80 nM. Importantly,
primary OT-1 T cells have a lower CD8 expression level than T1.CD8+
cells ranging from 1 to 3 [72]. Using the 4P ligand affinity as surrogate
for the OVA ligand affinity, the potency is expected to range from 15 nM
to 40 nM. However, there is a certain affinity dependence of the potency
5 Competition binding model 68
for the stated range of CD8 expression level 11C. Using the 4V affinity
instead, to account for the temperature dependence of the affinity, yields a
predicted range of the potency from 30 nM to 100 nM in agreement with the
measurements. Thus, the data indicates that the potency of cognate ligand
is largest for T1.CD8- cells (CD8 low, Fig. 12C), becomes smaller for OT-1
cells (CD8 mid, Fig. 12D), and assumes the lowest value for T1.CD8+ cells
(CD8 high, Fig. 12B). Taken together, the findings provide evidence that
the potency does indeed depend on the CD8 expression level in agreement
with the fourth prediction. However, the issue that the peaks of CD69
up-regulation of T1.CD8- cells (Fig. 12A) are at such low concentrations
remains unresolved.
6 Competition binding model and antigen pre-
senting cells
CBM indicates that the interactions between pMHC, TCR, and CD8 en-
hance sensitivity for foreign antigen as well as self tolerance in response
to self peptides. Thus, CD8 does not only facilitate T cell activation in
response to an infection, but also contributes to self tolerance via the high
affinity interaction between pMHC and the CD8 binding site of the TCR-
CD8 complex. However, the findings so far were obtained for soluble lig-
ands. Under natural conditions, T cells interact with APCs. For this
reason, CBM is put in context of APCs via a model of pMHC presentation
and infection of APCs that allows for bivalent engagement between pMHC
and T cell surface receptors TCR and CD8.
6.1 Modeling of pMHC presentation
In Sec. 5.2, TCR activity was determined by the amount of multivalently
bound TCRs in direct contact with pMHC. To keep this notion, the model
of pMHC presentation assumes that pMHC can physically engage each
other leading to the formation of pMHC clusters on the surface of APCs
[25]. For the sake of simplicity, only single pMHC and bivalent clusters
are considered. Furthermore, the presented pMHC can either arise from
low affinity self peptides or from high affinity foreign antigen. Hence, five
distinct ligand states can form on the surface of APCs (Fig. 13A): single
self pMHC S, single foreign pMHC A, homo-dimerized self pMHC SS,
homo-dimerized foreign pMHC AA, and hetero-dimerized self and foreign
pMHC AS. The densities of these five ligand states are determined by
the total density of pMHC on an APC surface Ptot, the degree of infection
ω, and the association constant for cluster formation KC . The degree of
infection is defined as the fraction of pMHC on the APC surface stemming
69
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Figure 13: Model of pMHC presentation by APCs
(A) The five possible ligand states on infected APCs: single self pMHC (blue), single foreign pMHC
(red), homo-dimerized self pMHC, homo-dimerized foreign pMHC, and hetero-dimerized self and foreign
pMHC. (B) Dimerization of pMHC is determined by a single association constant KC that cannot
discriminate between self peptide and foreign antigen. (C) Cluster density in units of total pMHC
density Ptot in dependence on degree of infection ω for the five ligand states as indicated. The dashed
and full black lines represent the total densities of single and dimerized pMHC, which are independent
of ω. For the association constant holds KC Ptot = 10.
from foreign antigens, and the association constant does not distinguish
between self peptides and foreign antigen (Fig. 13B). At steady state, the
set of equations describing the ligand states on the APC is given by
ω Ptot = A+ 2 ·AA+AS , (59a)
(1− ω)Ptot = S + 2 · SS +AS , (59b)
AA =
1
2
KC A
2 , (59c)
SS =
1
2
KC S
2 , (59d)
AS = KC A · S . (59e)
The first two equations describe the conservation of foreign antigen respec-
tively self peptides. The factor of 2 in front of the term AA in Eq. (59a),
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respectively SS in Eq. (59b), arises from the number of foreign, respectively
self, pMHC in the homo-dimerized complex. The next three equations are
the relations between the densities of dimerized and single pMHC. The
prefactor of 1/2 in Eqs. (59c) and (59d) is due to the stoichiometry of
homo-dimerization. Note that the sum of Eqs. (59a) and (59b) expresses
the conservation of total pMHC. Furthermore, defining the total density of
single pMHC by P1 ≡ A+ S and the total density of dimerized pMHC by
P2 ≡ AA+ SS +AS, one finds
Ptot = P1 + 2P2 , (60a)
P2 =
1
2
KC P
2
1 . (60b)
This means that the total densities of single pMHC and bivalent clusters
are independent of the degree of infection. This is a reflection of KC not
depending on the nature of pMHC, and implies that APCs are not them-
selves able to distinguish self peptides from foreign antigen. Hence, in terms
of cluster size distribution, APCs present an unbiased pool of pMHC, and
ligand discrimination falls entirely in the realm of T cells.
The densities of the ligand states in dependence on the degree of
infection are shown in Fig. 13C for an association constant KC Ptot = 10.
Varying the degree of infection from ω = 0 to ω = 1, the ligand states
containing only self pMHC (S and SS) decline while the ligands states
build up from foreign antigen (A and AA) increase continuously in density.
The density of bivalent cluster containing one self and one foreign pMHC
(AS) exhibits a peak at ω = 1/2, because at this condition the individual
constituents are present at equal amounts. As pointed out above, the total
densities of single pMHC (P1) and dimerized pMHC (P2) are independent
of the degree of infection.
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6.2 Model parameters and rescaling
The model of pMHC presentation comprises of three parameters: the total
pMHC density Ptot, the degree of infection ω, and the association constant
for cluster formation KC . Including CBM adds further eight parameters:
the self pMHC-TCR affinity KS , the foreign pMHC-TCR affinity KA, the
pMHC-CD8 affinity K ′, the association constant of TCR-CD8 complex
formation Q1, the effective association constant for the formation of aggre-
gated state Ξ, the association constant of TCR binding to pMHC-bound
CD8 Q4, the total TCR density RT , and the total CD8 density RC . Impor-
tantly, the affinities are distinct from those used for soluble ligands as now
the interaction between two cell surfaces is considered. Hence, the affinities
have the unit of an inverse two-dimensional density, just as Q1, Ξ, Q4, and
KC . The TCR density is used as reference density leading to the following
definitions of dimensionless model parameters,
κS ≡ RT KS , (61a)
κA ≡ RT KA , (61b)
κ′ ≡ RT K ′ , (61c)
q1 ≡ RT Q1 , (61d)
ξ ≡ RT Ξ , (61e)
q4 ≡ RT Q4 , (61f)
kC ≡ RT KC , (61g)
ρC ≡ RC/RT , (61h)
ρP ≡ Ptot/RT . (61i)
Note that the definitions of q1, ξ, and q4 match the ones in Sec. 3.3.
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6.3 Binding polynomial
Having established a model for pMHC presentation by APCs, the interac-
tions with the T cell surface receptors via CBM need to be determined. As
in Sec. 3.4, this is carried out in the framework of binding polynomials.
CBM allows for four different ways of how pMHC can be bound to T cell
surface receptors (see Chap. 3). These are reflected in the scaffold expres-
sions (24). Tallying these expressions, on the one hand for self peptide with
low affinity κS and on the other hand for foreign antigen with high affin-
ity κA, leads to auxiliary binding polynomials for self, respectively foreign,
pMHC,
FS(T,C) := κS T
(
1 + ξ C
)
+ κ′C
(
1 + q4 T
)
, (62a)
FA(T,C) := κA T
(
1 + ξ C
)
+ κ′C
(
1 + q4 T
)
. (62b)
Using expressions (62), the complete binding polynomial of CBM in the
context of APCs is given by
F (T,C, S,A) := T+C+q1 T C+S·
[
1+FS(T,C)
]
+A·[1+FA(T,C)]+
1
2
kC S
2 · [1 + FS(T,C)]2 + 1
2
kC A
2 · [1 + FA(T,C)]2+
kC A·S ·
[
1+FS(T,C)+FA(T,C)+FS(T,C)·FA(T,C)
]
. (63)
The first three terms describe unbound TCR T , unbound CD8 C, and the
TCR-CD8 complex forming with association constant q1. The subsequent
terms denote the different ligand states and their interactions with T cell
surface receptors (Fig. 14). First, single self pMHC S and its binding
to T cell surface receptors S · FS(T,C) is specified. This is followed by a
similar term for single foreign pMHC. Next, homo-dimerized self pMHC is
described. It can be unbound, SS (see Eq. (59d)), one of the two subunits
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SS·FS(T,C) AA·FA(T,C)
AS·FS(T,C) AS·FA(T,C)
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Figure 14: Binding states of CBM in context of APCs
In the first three rows, the four basic ligand-receptor binding states of CBM for single self and single
foreign pMHC (first row), homo-dimerized self and foreign pMHC (second row), and hetero-dimerized
pMHC (third row) are show. The remaining rows give the bivalent states of CBM with homo-dimerized
self pMHC (fourth row), homo-dimerized foreign pMHC (fifth row), and hetero-dimerized pMHC (last
two rows). The respective state densities are expressed in terms of the auxiliary binding polynomials
(62) and the corresponding pMHC densities (see, Sec. 6.1) indicated by the parentheses.
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can be bound, 2SS ·FS(T,C), or both subunits are bound, SS ·FS(T,C)2.
The same holds for homo-dimerized foreign pMHC, which is given there-
after. Finally, hetero-dimerized self and foreign pMHC is characterized.
It can be unbound, AS (see Eq. (59e)), only the self pMHC subunit can
be bound, AS · FS(T,C), only the foreign pMHC subunit can be bound,
AS ·FA(T,C), or both subunits made contact with T cell surface receptors,
AS · FS(T,C) · FA(T,C). Thus, expression (63) tallies all possible model
states and is therefor the binding polynomial of CBM in the context of
APCs.
For fixed parameters, the unknown variables are the densities of
unbound TCR T , unbound CD8 C, unbound single self pMHC S, and
unbound single foreign pMHC A. As outlined in Sec. 3.4, these variables
are determined by solving a set of equations describing the conservation of
the respective total densities. These equations are given by
1 = T
∂F (T,C, S,A)
∂T
, (64a)
ρC = C
∂F (T,C, S,A)
∂C
, (64b)
(1− ω) ρP = S ∂F (T,C, S,A)
∂S
, (64c)
ω ρP = A
∂F (T,C, S,A)
∂A
. (64d)
From top to bottom, these relations describe the conservation of total TCR,
CD8, self pMHC, and antigenic pMHC. The solutions of Eqs. (64) are
denoted with T¯ , C¯, S¯, and A¯. Based on these, the density of each binding
state can be calculated and consequently of each observable of interest.
6.4 T cell activation
The notion of T cell receptor activity is directly adapted from Sec. 5.2.
There, only states with at least two TCRs in direct contact with pMHC
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were assumed to be signaling states, and in these states only TCRs in
direct contact with pMHC were taken to be signaling. Further, it was dis-
tinguished between strong and weak signaling TCRs depending on whether
a CD8 molecule was bound to the signaling TCR or not. The same is as-
sumed for CBM in context of APCs. In Fig. 14, weak and strong signaling
TCRs are indicated by subjacent thin, respectively thick, arrows. The
corresponding densities, yws and yss, are given by
yws(ω, κA, ρC) := kC
(
1 + ξ C¯
) [(
κS S¯ + κA A¯
)
T
]2
, (65a)
yss(ω, κA, ρC) := ξ C¯ · yws(ω, κA, ρC) , (65b)
and taken to be functions of the degree of infection ω, the affinity of foreign
antigen κA, and the CD8 expression level ρC . The remaining parameters
are fixed in the following . The parameters q1, ξ, and q4 are exactly defined
as in the case of soluble ligands, and their values are thus assumed to be the
same as in Chap. 5 (see the most right column of Tab. 5). The total pMHC
density [20] and total TCR density [15] were estimated to be roughly the
same. Hence, the total dimensionless total pMHC density is set to ρP = 1.
No values of two-dimensional absolute affinities for pMHC-TCR or pMHC-
CD8 interactions have been reported so far. Thus, these quantities have to
be guessed. In order to be positively selected, TCRs must weakly interact
with self pMHC [52]. Therefore, a small pMHC-TCR affinity is imposed
for self peptides, κS = 10
−2. The pMHC-TCR affinities of cognate ligands
are assumed to be 102, and antigen affinities are expected to lie in the
range between self peptides and cognate ligands. The pMHC-CD8 affinity
is assumed to have a moderate value. Hence, κ′ = 1 is chosen. This yields
an affinity of ≈ 40 for the CD8 binding site of a TCR-CD8 complex. Finally,
the association constant for pMHC cluster formation on APCs is set to the
same value as in Fig. 13C, i.e. kC = 10.
The model of TCR activity is exactly the same as in Sec. 5.2, and
thus given by the weighted sum of weak and strong signaling TCRs (see
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Eq. (57) with η ≡ 1),
yact(ω, κA, ρC , ψ) := yws(ω, κA, ρC) + ψ yss(ω, κA, ρC) . (66)
and is taken to be a function of the degree of infection ω, the affinity of
foreign antigen κA, the CD8 expression level ρC , and the enhancement
factor ψ describing the impact of CD8 on TCR signaling. In the following,
it is investigated how different values of ρC and ψ influence self tolerance
and recognition of foreign antigen of different affinities. As measure for self
tolerance, the TCR activity that establishes if T cells interact with healthy
cells is used. It is defined by
yact,self(ρC , ψ) := yact(0, 0, ρC , ψ) . (67a)
If yact,self(ρC , ψ) < yact,self(ρ
′
C , ψ), it is said that the CD8 expression level
ρC improves self tolerance compared to ρ
′
C . Next, a measure for sensitivity
towards foreign antigen is required. The basic idea is that a minimal TCR
activity y∗act needs to be established in order to trigger T cell activation.
The smallest degree of infection ω∗ for which y∗act is reached shall serve as
measure for sensitivity towards foreign antigen with affinity κA. It is given
by
yact(ω, κA, ρC , ψ)
!
= y∗act ⇒ ω = ω∗(κA, ρC , ψ, y∗act) . (67b)
A T cell with CD8 expression level ρC is said to be the more sensitive
towards an antigen of affinity κA the smaller ω
∗(κA, ρC , ψ, y∗act).
Using the parameter values specified above, a healthy APC estab-
lishes a TCR activity of 7× 10−5 in the absence of CD8. To assure that
this activity is well below threshold, a minimal TCR activity of y∗act = 10−3
is used in the following. The TCR activity of healthy cells in dependence
on CD8 expression level ρC and for various values of enhancement factor ψ,
ranging from 50 to 1000, is shown in Fig. 15A. The dashed lines indicate
the minimal TCR activity y∗act. For all values of ρC and ψ, the amount
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Figure 15: Self tolerance and sensitivity for CBM in context of APCs
(A) Full curves show TCR activity of healthy APCs (ω = 0) in dependence on the CD8 expression
level ρC for various values of ψ. The dashed lines indicate the minimal TCR activity needed to trigger
T cell activation, y∗act = 10
−3. The remaining parameters are specified in the main text on p. 76.
(B) The smallest detectable degree of infection ω∗ in dependence on the CD8 expression level ρC for
various values of ψ. Different antigens are given by different affinities κA and are indicated by color.
The remaining parameters are as in (A).
of TCR activity established is insufficient to trigger T cell activation. For
ψ = 50 and ψ = 100, self tolerance continuously improves with increasing
ρC approaching about 10
−6 (ψ = 50), respectively 2× 10−6 (ψ = 100), as
ρC → 10. However, for ψ = 500 and ψ = 1000, the TCR activity initially
increases before a decline sets in. The TCR activity found for ρC = 0 is
assumed again at CD8 expression level ρC = 1.4 (ψ = 500), respectively
ρC = 2.7 (ψ = 1000). As ρC → 10, the TCR activity approaches 10−5
(ψ = 500), respectively 2× 10−5 (ψ = 1000). Thus, self tolerance is in gen-
eral improved by CD8, showing that this aspect of the findings in Chap. 5
is recovered in the context of APCs.
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The smallest detectable degree of infection ω∗ in dependence on
CD8 expression level ρC and for various values of enhancement factor ψ,
ranging from 50 to 1000, and different antigen affinities between 10−1 and
102 is shown in Fig. 15B. As specified above, the affinity of self peptides
is κS = 10
−2. In the absence of CD8, the different affinity antigens yield
values for ω∗ of 0.35 (κA = 10−1), 0.057 (κA = 100), 0.031 (κA = 101),
and 0.028 (κA = 10
2). The lowest affinity antigen (κA = 10
−1) cannot be
detected for ρC > 1.1 if ψ = 50, respectively ρC > 2 if ψ = 100, because
the T cell fails to establish the minimal required TCR activity due to the
competitive effect of CD8. For ψ = 500 and ψ = 1000, ω∗ initially improves
to 0.19 at ρC = 0.4 (ψ = 500), respectively 0.11 at ρC = 0.4 (ψ = 1000),
after which an increase sets in, intersecting the values of ρC = 0 at ρC = 1.6
(ψ = 500) and ρC = 3.2 (ψ = 1000), to finally approach 0.94 (ψ = 500),
respectively 0.63 (ψ = 1000), as ρC → 10. Thus, for κA = 10−1, improved
sensitivity is encountered only for ψ = 500 and ψ = 1000 if the CD8
expression level is not too high.
For antigens with affinity κ = 100, the smallest detectable degree of
infection continuously increases with ρC for ψ = 50, and reaches a value of
0.3 as ρC → 10. For the larger values of ψ, ω∗ initially declines before an
increase sets in. While only a little bump is found for ψ = 100, the minimal
value of ω∗ is given by 0.025 at ρC = 0.5 for ψ = 500, respectively 0.014 at
ρC = 0.6 for ψ = 1000. The value at ρC = 0 is assumed again at ρC = 3.9
(ψ = 500) and at ρC = 9.5 (ψ = 1000), respectively. For ρC → 10, ω∗ is
given by 0.20 (ψ = 100), 0.087 (ψ = 500), and 0.058 (ψ = 1000). As for
κA = 10
−1, only for ψ = 500 and ψ = 1000 improved sensitivity is found,
though on a broader range of CD8 expression levels.
For antigen affinity of κA = 10
1, an initial decline of ω∗, followed
by an increase, is found for all values of ψ. The minimal values are 0.024
at ρC = 1.5 for ψ = 50, 0.017 at ρC = 1.7 for ψ = 100, 0.007 at ρC = 1.5
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for ψ = 500, and 0.004 at ρC = 1.2 for ψ = 1000. As ρC → 10, the
smallest detectable degrees of infection approach 0.035 for ψ = 50, 0.024
for ψ = 100, 0.010 for ψ = 500, and 0.007 for ψ = 1000. Thus, only for
ψ = 50, ω∗ rises above the value at ρC = 0, which happens at ρC = 6.4,
and sensitivity is only improved if ρC becomes not too large. For the other
values of ψ, increased sensitivity due to CD8 is found for all CD8 expression
levels considered, with minimal values are found for ρC between 1 and 2.
Finally, antigens with affinity κA = 10
2 cause a continuous decline
in ω∗ with increasing ρC for all values of ψ. The values ω∗ is approaching
as ρC → 10 are given by 0.009 (ψ = 50), 0.007 (ψ = 100), 0.003 (ψ = 500),
and 0.002 (ψ = 1000), respectively. Though, most of the decline is found
for CD8 expression levels ρC < 3 after which ω
∗ remains almost constant.
The preceding results indicate that, in the presence of CD8, the
highest affinity ligands can be sensed if their proportion in the pMHC
pool is only a few per mille. Experimentally, it was found that a 1 to
10 cognate antigens are sufficient to trigger a T cell [38]. To translate
the computed proportions into the number of cognate pMHC that can be
detected, the following considerations shall serve as estimate. The part of
the T cell surface in contact with an APC was specified to be about 5 % [33].
Further, the total number of TCRs on the T cell surface is approximately
20 000 (Tab. 2). Thus, the number of TCRs in the contact zone is roughly
1000. Assuming the contact area of the APC to be of the same size as the
contact area of the T cell, the total number of pMHC with which the TCRs
interact is also roughly 1000, due to the similarity of the TCR and pMHC
densities [15, 20]. Hence, detection of foreign pMHC with a proportion of
only a few per mille in an otherwise vast pool of self peptides corresponds
to sensing a number of order 1 foreign antigens.
The obtained levels of CD8 expression for which improved self tol-
erance and improved sensitivity are found are summarized in Fig. 16. The
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Figure 16: Impact of CD8 on self tolerance and sensitivity
CD8 expression levels ρC for which self tolerance and sensitivity are improved compared to the absence
of CD8 for various antigen affinities κA and enhancement factors ψ. Red lines show regions of ρC with
improved self tolerance, defined by yact,self(ρC , ψ) < yact,self(0, ψ), green lines regions with improved
sensitivity, defined by ω∗(κA, ρC , ψ, y∗act) < ω
∗(κA, 0, ψ, y∗act), and black lines regions where both quan-
tities are improved. The TCR activity threshold is set to y∗act = 10
−3. The remaining parameters are
specified in the main text on p. 76.
red lines indicate CD8 expression levels with improved self tolerance com-
pared to the absence of CD8, i.e. yact,self(ρC , ψ) < yact,self(0, ψ). The green
lines show the same but for improved sensitivity, i.e. ω∗(κA, ρC , ψ, y∗act) <
ω∗(κA, 0, ψ, y∗act). As expected, the two effects are complementary. But
there are expression levels of CD8 for which both beneficial effects are es-
tablished simultaneously (black lines). This includes the value ψ = 100
used in Chap. 5. However, the sensitivity of the highest affinity ligand
drops hardly below the percent limit (Fig. 15B), which is not in good
agreement with requirement to sense an order 1 number of foreign anti-
gens. For ψ = 500, on the other hand, the sensitivity requirements are
fulfilled (Fig. 15B). Further, the finding in Sec. 5.3 that the 4S ligand does
not trigger CD69 up-regulation in the presence of CD8 is also in agreement
with this value. Thus, simultaneous improvements of self tolerance and
sensitivity are recovered in the context of APCs.

7 Discussion and Conclusions
The focus of this work is on the role of the co-receptor CD8 in ligand dis-
crimination and T cell activation. In particular, the interplay of TCR and
CD8 with pMHC was scrutinized by developing a family of mathemati-
cal binding models, and the contribution of CD8 on intracellular signaling
was investigated. Based on findings reported in the literature, a family
of pMHC-TCR-CD8 binding models was developed that systematically in-
corporates CD8-related interactions. Each probed pMHC-TCR-CD8 in-
teraction model was confronted with data from accurately measured dose
response assays, which were conducted by Sumit Deswal at the Univer-
sity of Freiburg, Germany, in the group of Prof. Dr. Wolfgang Schamel.
Although T cells react with APCs under physiological conditions, soluble
pMHC tetramers were used as ligands. This allowed high control over the
dose to which the T cells were exposed. Further aspects of data acquisition,
like prevention of receptor internalization, were readily taken into account
by the modeling approach. The data was gathered for a wide range of ex-
perimental conditions, i.e. different cell and ligand types as well as various
ligand doses, allowing for the identification of a best-fitting model as well
as the corresponding model parameters.
The best-fitting model, termed Competition Binding Model (CBM,
see Fig. 2G), comprises peptide-specific binding between pMHC and TCR,
peptide-unspecific binding between pMHC and CD8, simultaneous binding
of TCR and CD8 to the same pMHC, as well as an interaction between the
two types of T cell surface receptors yielding a TCR-CD8 complex possess-
ing two binding sites – one from the TCR and the other one from CD8,
making the latter peptide-unspecific. The most notable finding revealed in
the course of parameter estimation was that the CD8 binding site of the
TCR-CD8 complex exhibits a much larger affinity for MHC than CD8 alone
(about 40-fold for parameters θ∗ in Tab. 5). As pMHC, if it is only bound
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to the CD8 binding site of a TCR-CD8 complex, is not in direct contact
with the TCR, no proximal TCR signaling (e.g. ITAM phosphorylation)
is expected. However, because this interaction involves a TCR and is of
high affinity, it is in direct competition with productive, i.e. potentially
signal-inducing, binding of pMHC to TCR.
The notion that pMHC can be simultaneously bound by a TCR and
a CD8 has been proposed before [30, 86]. Multiple evidence also suggests
that TCR and CD8 can engage in some way [77, 29, 5]. One possible source
of such an interaction is the α-chain connecting peptide motif found on the
TCR [55, 48]. A further study proposed that engagement of TCR and CD8
is mediated by the kinase Lck [41]. Further, co-localization of TCR and
CD8 in the absence of ligands has also been reported [28]. Hence, the way
TCR-CD8 interaction has been included into CBM is in agreement with
previous findings. However, a TCR-related increase of pMHC-CD8 affinity
has not yet been claimed. In this respect, CBM is a hypothesis requiring
further independent proof by experiments.
Based on a simple model of TCR triggering, CBM is capable to qual-
itatively predict the up-regulation of key markers of T cell activation. The
data was provided by our collaboration partners Sumit Deswal and Prof.
Dr. Wolfgang Schamel from the University of Freiburg, Germany. The
TCR triggering model builds up on the observation that soluble monomeric
pMHC is insufficient to induce T cell responses [6, 74] considering only those
TCRs as signaling competent that are multivalently bound and in direct
contact with pMHC (see Fig. 4). It further connects the association con-
stant of multivalent binding to the pMHC-TCR affinity enabling affinity-
based ligand discrimination. The TCR triggering model is related to the
permissive geometry model [50], which states that only multivalently bound
TCRs undergo a conformational change making them susceptible to further
biochemical modifications (e.g. phosphorylations) and hence initiators of
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intracellular signaling [70]. The dynamics of these modifications were not
outlined in any detail in this work. Instead, it was simply assumed that
the signal intensity emanated by a conformationally changed TCR does not
depend on any ligand property, and was thus set to 1. Hence, it is only the
pMHC-TCR affinity determining whether a ligand is capable of inducing
a sufficient intracellular signal intensity to launch a T cell response. How-
ever, extensions to this simplified point of view are possible. For example,
kinetic proofreading predicts that the signal intensity also depends on the
ligand’s rate of dissociation from the TCR and the number of modification
steps necessary to activate the TCR [49]. Such further dependencies of the
intracellular signal can not be excluded, but there is no clear evidence in the
activation data used in this work pointing towards additional mechanisms
of signal assembly.
The impact of co-receptor CD8 on intracellular signaling was incor-
porated in the simplest conceivable way. If CD8 is bound to a conformation-
ally changed TCR, the emanated signal intensity is increased by a factor
ψ > 1. This assumption is justified by the observation that CD8 binds the
kinase Lck [83, 79], and thereby recruits the most critical kinase of ITAM
phosphorylation to the TCR [7]. This enhancement of signal generation,
together with the property of CBM to provide a high affinity competitor
for productive pMHC-TCR contacts, introduces a novel mechanism for the
role of CD8 in ligand discrimination and T cell activation that improves
self tolerance as well as sensitivity towards foreign antigen of T cells. Low
affinity (self) ligands fail to overcome the obstacle provided by the high
affinity CD8 binding site of the TCR-CD8 complex leading to a diminished
amount of conformationally changed TCRs. Thus, a reduced intracellular
signal intensity in the presence of CD8 is found in response to self pep-
tides. High affinity (foreign) ligands counteract this interaction by forming
pMHC-TCR bonds with TCR-CD8 complexes and thereby benefiting from
the CD8-related enhancement of signal generation. This induces increased
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intracellular signal intensity in the presence of CD8, and thus facilitates T
cell activation in response to foreign antigen. Importantly, an enhancing
impact of CD8 on T cell activation has been observed before [36, 46] and
could also be confirmed experimentally in this work.
The notion that multivalent binding is necessary to induce a cellular
response is not limited to T cells. In fact, this requirement is found for many
transmembrane receptors, for example epidermal growth factor receptors
[68], platelet derived growth factor receptors [34], the high affinity receptor
for IgE (FcεRI) [39, 37], B cell receptors [9, 60], and ephrin receptors [71],
showing that ligand discrimination based on multivalent binding is a very
common mechanism in biology. Thus, the findings in this work might also
be of relevance for other systems than T cells.
A further important aspect underlying this work is the consistency
of the experimental approach. In many studies, affinity measurements were
conducted in one system, e.g. by surface plasmon resonance or pMHC
tetramer binding, and were then correlated to T cell activation measured
in another one, like T cell stimulation by APCs [42, 36, 3, 46, 12, 2, 22].
By contrast, the relation between ligand affinity and T cell activation was
established for the same system in this work enabling the formulation of a
quantitative model on the interactions of pMHC, TCR, and CD8 for the
first time.
The successful application of CBM to soluble ligands motivated
the investigation in the context of APCs. Based on a model of pMHC
presentation that includes ligand clustering on the surface of APCs [25], and
using the same TCR triggering model as for soluble ligands, simultaneous
improvements of self tolerance and antigen sensitivity were recovered in this
system. Furthermore, the degree of infection of cognate ligands that can
be sensed by a T cell was found to be as low as a few per mille. This small
proportion translates into a number of order 1. Strikingly, T cell responses
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to such small numbers of cognate ligands embedded in vast number of self
peptides have been observed experimentally [38]. Thus, CBM is capable of
explaining this finding, and importantly, no sacrifices of self tolerance have
to be made.
In conclusion, the statistically rigorous confrontation of a family
of pMHC-TCR-CD8 binding models with accurate dose response data re-
sulted in the identification of an interaction model that, in combination with
a multivalent TCR triggering model, suggests a novel mechanism to am-
plify affinity-based ligand discrimination, in which a dual role is attached to
CD8. On the one hand, CD8 hampers the formation of productive pMHC-
TCR contacts, and on the other hand enhances intracellular signaling once
such productive contacts have been made. The crux of the proposed mecha-
nism is that the decision which of the two opposing effects comes into effect
is solely determined by the pMHC-TCR affinity. This leads to improved
self tolerance in response to self peptides (low affinity) and to increased
sensitivity towards foreign antigen (high affinity). Hence, the mechanism
by which CD8 contributes to ligand discrimination and T cell activation
was refined in this work pointing to an important role of CD8 in T cell
immunity.
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A Results of Model G2
In the following, the results obtained for Model G2, the binding model
G (see Fig. 2G) with effective ligand valency f = 2, are discussed. In
Fig. 17A, the best fit (solid lines) of Model G2 together with the standard
deviation of individual measurements (shaded areas), as obtained from the
error model (see Sec. 4.2), and the binding data (dots) are shown. The top
row shows T1.CD8- cells and the bottom row T1.CD8+ cells. The ligand
types are indicated by color. As for Model G3 (see Fig. 7), the agreement
between model and data is very good.
The 95 % confidence intervals were estimated using the profile like-
lihood method (see Sec. 2.3), and are shown in Fig. 17B. All parameters
are completely identifiable, except of q1 and ξ, which have only an upper
bound. The values of the dissociation constants, i.e. the inverses of the
affinities, of the 4L and 4P ligand lie between 0.1 µM and 1 µM, between
0.3 µM and 3 µM for the 4V ligand, between 6 µM and 40 µM for the 4S
ligand, and between 1.5 µM and 20 µM for pMHC-CD8. These intervals
contain the reported values of cognate ligands and murine CD8 [18, 30].
The multivalent engagement parameter κMV lies between 5 µM and 30 µM.
The MLE value of the dimensionless association constant of multivalent
binding for the 4P ligand, κMVK1,4P assumes a value of about 10, which
is similar to the value found for Model G3, and is in good agreement with
previously reported values on such dimensionless multivalent binding con-
stants [35, 23, 73].
The association constant for pMHC-independent TCR-CD8 com-
plex formation q1 is zero for the best fit and has an upper bound of 0.1.
Thus, up to 55 % of the TCRs on T1.CD8+ cells might be bound to CD8
in the absence of ligands. This fraction does also depends on the CD8 ex-
pression level in a monotonically decreasing way. As for Model G3 , the
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Figure 17: Fitting results of Model G2
(A) Best fit: the same as Fig. 7 but for Model G2. (B) Profile likelihoods: the same as Fig. 8 but for
Model G2.
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association constant of TCR-CD8 complex formation if pMHC is bound to
CD8, q4, is significantly larger than q1, while ξ and q1 are quite similar.
This leads to the same implications as for Model G3. Hence, Model G2
and G3 behave qualitatively identical.
The probability to not form a covalent bond between a pMHC-TCR
contact upon UV-light irradiation, pUV, has an upper bound of 0.8. This
means that at least 20 % of the pMHC-TCR contacts develop a covalent
connection during UV-light exposure. The value of KW is located in the
range from 0.1 µM−1 to 1 µM−1. And lastly, the scaling factor M∗ lies
between 0.6 and 0.8.
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